메뉴 건너뛰기




Volumn 2017, Issue 11, 2017, Pages

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 85035141703     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004063.pub4     Document Type: Review
Times cited : (105)

References (259)
  • 1
    • 24944465318 scopus 로고    scopus 로고
    • Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
    • 2974321
    • Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. Journal of Clinical Oncology 2005;23(24):5660-7. 2974321
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.24 , pp. 5660-5667
    • Ajani, J.A.1    Fodor, M.B.2    Tjulandin, S.A.3    Moiseyenko, V.M.4    Chao, Y.5    Cabral Filho, S.6
  • 2
    • 84886788915 scopus 로고    scopus 로고
    • Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study
    • 2974323
    • Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. European Journal of Cancer 2013;49(17):3616-24. 2974323
    • (2013) European Journal of Cancer , vol.49 , Issue.17 , pp. 3616-3624
    • Ajani, J.A.1    Buyse, M.2    Lichinitser, M.3    Gorbunova, V.4    Bodoky, G.5    Douillard, J.Y.6
  • 3
    • 77951888102 scopus 로고    scopus 로고
    • Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
    • 7139593
    • Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. Journal of Clinical Oncology 2010;28(9):1547-53. 7139593
    • (2010) Journal of Clinical Oncology , vol.28 , Issue.9 , pp. 1547-1553
    • Ajani, J.A.1    Rodriguez, W.2    Bodoky, G.3    Moiseyenko, V.4    Lichinitser, M.5    Gorbunova, V.6
  • 4
    • 84939460469 scopus 로고    scopus 로고
    • Clinical benefit and health-related quality of life assessment in patients treated with cisplatin/S-1 versus Cisplatin/5-FU: secondary end point results from the first-line advanced gastric cancer study (FLAGS)
    • 7139594
    • Bodoky G, Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, et al. Clinical benefit and health-related quality of life assessment in patients treated with cisplatin/S-1 versus Cisplatin/5-FU: secondary end point results from the first-line advanced gastric cancer study (FLAGS). Journal of Gastrointestinal Cancer 2015;46(2):109-17. 7139594
    • (2015) Journal of Gastrointestinal Cancer , vol.46 , Issue.2 , pp. 109-117
    • Bodoky, G.1    Scheulen, M.E.2    Rivera, F.3    Jassem, J.4    Carrato, A.5    Moiseyenko, V.6
  • 5
    • 41149154862 scopus 로고    scopus 로고
    • Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
    • 2974326
    • Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology 2008;26(9):1435-42. 2974326
    • (2008) Journal of Clinical Oncology , vol.26 , Issue.9 , pp. 1435-1442
    • Al-Batran, S.E.1    Hartmann, J.T.2    Probst, S.3    Schmalenberg, H.4    Hollerbach, S.5    Hofheinz, R.6
  • 6
    • 84873720456 scopus 로고    scopus 로고
    • The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
    • 2974328
    • Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). European Journal of Cancer 2013;49(4):835-42. 2974328
    • (2013) European Journal of Cancer , vol.49 , Issue.4 , pp. 835-842
    • Al-Batran, S.E.1    Pauligk, C.2    Homann, N.3    Hartmann, J.T.4    Moehler, M.5    Probst, S.6
  • 7
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    • 2974330
    • Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97. 2974330
    • (2010) Lancet , vol.376 , Issue.9742 , pp. 687-697
    • Bang, Y.J.1    Van Cutsem, E.2    Feyereislova, A.3    Chung, H.C.4    Shen, L.5    Sawaki, A.6
  • 9
    • 84865429022 scopus 로고    scopus 로고
    • Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    • 2974332
    • Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer 2012;15(3):313-22. 2974332
    • (2012) Gastric Cancer , vol.15 , Issue.3 , pp. 313-322
    • Sawaki, A.1    Ohashi, Y.2    Omuro, Y.3    Satoh, T.4    Hamamoto, Y.5    Boku, N.6
  • 10
    • 80054990461 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial
    • 2974333
    • Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. British Journal of Cancer 2011;105(9):1273-8. 2974333
    • (2011) British Journal of Cancer , vol.105 , Issue.9 , pp. 1273-1278
    • Shiroiwa, T.1    Fukuda, T.2    Shimozuma, K.3
  • 11
    • 0030789850 scopus 로고    scopus 로고
    • Randomised phase II study of cisplatin and 5-fluorouracil (5-Fu) versus cisplatin alone in advanced squamous cell oesophageal cancer
    • 2974335
    • Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-Fu) versus cisplatin alone in advanced squamous cell oesophageal cancer. European Journal of Cancer 1997;33(8):1216-20. 2974335
    • (1997) European Journal of Cancer , vol.33 , Issue.8 , pp. 1216-1220
    • Bleiberg, H.1    Conroy, T.2    Paillot, B.3    Lacave, A.J.4    Blijham, G.5    Jacob, J.H.6
  • 13
    • 21244437063 scopus 로고    scopus 로고
    • Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
    • 2974338
    • Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. British Journal of Cancer 2005;92(11):1976-83. 2974338
    • (2005) British Journal of Cancer , vol.92 , Issue.11 , pp. 1976-1983
    • Sumpter, K.1    Harper-Wynne, C.2    Cunningham, D.3    Rao, S.4    Tebbutt, N.5    Norman, A.R.6
  • 14
    • 69249222615 scopus 로고    scopus 로고
    • Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial
    • 2974340
    • Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Quality of Life Research 2009;18(7):853-61. 2974340
    • (2009) Quality of Life Research , vol.18 , Issue.7 , pp. 853-861
    • Curran, D.1    Pozzo, C.2    Zaluski, J.3    Dank, M.4    Barone, C.5    Valvere, V.6
  • 15
    • 48849094297 scopus 로고    scopus 로고
    • Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
    • 2974341
    • Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology 2008;19(8):1450-7. 2974341
    • (2008) Annals of Oncology , vol.19 , Issue.8 , pp. 1450-1457
    • Dank, M.1    Zaluski, J.2    Barone, C.3    Valvere, V.4    Yalcin, S.5    Peschel, C.6
  • 16
    • 33750831270 scopus 로고    scopus 로고
    • Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial)
    • 2974343
    • Duffour J, Bouche O, Rougier P, Milan C, Bedenne L, Seitz JF, et al. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Research 2006;26(5 B):3877-83. 2974343
    • (2006) Anticancer Research , vol.26 , Issue.5 B , pp. 3877-3883
    • Duffour, J.1    Bouche, O.2    Rougier, P.3    Milan, C.4    Bedenne, L.5    Seitz, J.F.6
  • 17
    • 84903547873 scopus 로고    scopus 로고
    • Gefitinib for oesophageal cancer progressing after chemotherapy (COG): aA phase 3, multicentre, double-blind, placebo-controlled randomised trial
    • 2974345
    • Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): aA phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncology 2014;15(8):894-904. 2974345
    • (2014) Lancet Oncology , vol.15 , Issue.8 , pp. 894-904
    • Dutton, S.J.1    Ferry, D.R.2    Blazeby, J.M.3    Abbas, H.4    Dahle-Smith, A.5    Mansoor, W.6
  • 18
    • 84874566567 scopus 로고    scopus 로고
    • Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
    • 2974347
    • Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Annals of Oncology 2013;24(3):710-8. 2974347
    • (2013) Annals of Oncology , vol.24 , Issue.3 , pp. 710-718
    • Eatock, M.M.1    Tebbutt, N.C.2    Bampton, C.L.3    Strickland, A.H.4    Valladares-Ayerbes, M.5    Swieboda-Sadlej, A.6
  • 20
    • 84891371156 scopus 로고    scopus 로고
    • Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
    • 2974351
    • Ford HER, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology 2014;15(1):78-86. 2974351
    • (2014) Lancet Oncology , vol.15 , Issue.1 , pp. 78-86
    • Ford, H.E.R.1    Marshall, A.2    Bridgewater, J.A.3    Janowitz, T.4    Coxon, F.Y.5    Wadsley, J.6
  • 21
    • 84892852372 scopus 로고    scopus 로고
    • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    • 7139595
    • Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9. 7139595
    • (2014) Lancet , vol.383 , Issue.9911 , pp. 31-39
    • Fuchs, C.S.1    Tomasek, J.2    Yong, C.J.3    Dumitru, F.4    Passalacqua, R.5    Goswami, C.6
  • 22
    • 85016976255 scopus 로고    scopus 로고
    • Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials
    • 7139596
    • Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, et al. Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. Journal of Clinical Oncology 2017 Feb [Epub ahead of print]; Vol. 35, issue 4 Suppl 3. [DOI: 10.1200/JCO.2017.35.4_suppl.3]7139596
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.4
    • Muro, K.1    Cho, J.Y.2    Bodoky, G.3    Goswami, C.4    Chao, Y.5    Dos Santos, L.V.6
  • 23
    • 73949087913 scopus 로고    scopus 로고
    • Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: A randomized controlled trial
    • 2974355
    • Huang JY, Sun Y, Fan QX, Zhang YQ. Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: A randomized controlled trial. Chinese Journal of Integrative Medicine 2009;7(11):1047-51. 2974355
    • (2009) Chinese Journal of Integrative Medicine , vol.7 , Issue.11 , pp. 1047-1051
    • Huang, J.Y.1    Sun, Y.2    Fan, Q.X.3    Zhang, Y.Q.4
  • 24
    • 84905028489 scopus 로고    scopus 로고
    • Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
    • 2974357
    • Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncology 2014;15(9):1007-18. 2974357
    • (2014) Lancet Oncology , vol.15 , Issue.9 , pp. 1007-1018
    • Iveson, T.1    Donehower, R.C.2    Davidenko, I.3    Tjulandin, S.4    Deptala, A.5    Harrison, M.6
  • 26
    • 0030065060 scopus 로고    scopus 로고
    • 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research
    • 2974360
    • Pouliquen X, Levard H, Hay J-M, McGee K, Fingerhut A, Langlois-Zantin O. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Annals of Surgery 1996;223(2):127. 2974360
    • (1996) Annals of Surgery , vol.223 , Issue.2 , pp. 127
    • Pouliquen, X.1    Levard, H.2    Hay, J.-M.3    McGee, K.4    Fingerhut, A.5    Langlois-Zantin, O.6
  • 27
    • 0037487245 scopus 로고    scopus 로고
    • Phase III clinical study of a new anticancer drug atofluding
    • 2974362
    • Li Q, Feng FY, Han J, Sui GJ, Zhu YG, Zhang Y, et al. Phase III clinical study of a new anticancer drug atofluding. Ai Zheng 2002;21(12):1350-3. 2974362
    • (2002) Ai Zheng , vol.21 , Issue.12 , pp. 1350-1353
    • Li, Q.1    Feng, F.Y.2    Han, J.3    Sui, G.J.4    Zhu, Y.G.5    Zhang, Y.6
  • 28
    • 84876951761 scopus 로고    scopus 로고
    • Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
    • 2974364
    • Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology 2013;14(6):490-9. 2974364
    • (2013) Lancet Oncology , vol.14 , Issue.6 , pp. 490-499
    • Lordick, F.1    Kang, Y.K.2    Chung, H.C.3    Salman, P.4    Oh, S.C.5    Bodoky, G.6
  • 29
    • 70349641356 scopus 로고    scopus 로고
    • Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
    • 2974366
    • Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Annals of Oncology 2009;20(10):1667-73. 2974366
    • (2009) Annals of Oncology , vol.20 , Issue.10 , pp. 1667-1673
    • Lorenzen, S.1    Schuster, T.2    Porschen, R.3    Al-Batran, S.E.4    Hofheinz, R.5    Thuss-Patience, P.6
  • 30
    • 84924415660 scopus 로고    scopus 로고
    • Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
    • 2974368
    • Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. European Journal of Cancer 2015;51(5):569-76. 2974368
    • (2015) European Journal of Cancer , vol.51 , Issue.5 , pp. 569-576
    • Lorenzen, S.1    Riera Knorrenschild, J.2    Haag, G.M.3    Pohl, M.4    Thuss-Patience, P.5    Bassermann, F.6
  • 31
    • 77949326012 scopus 로고    scopus 로고
    • A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
    • 2974370
    • Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology 2010;21(1):71-7. 2974370
    • (2010) Annals of Oncology , vol.21 , Issue.1 , pp. 71-77
    • Moehler, M.1    Kanzler, S.2    Geissler, M.3    Raedle, J.4    Ebert, M.P.5    Daum, S.6
  • 32
    • 0020079072 scopus 로고
    • Cyclophosphamide, doxorubicin and celetin intubation for inoperable oesophageal carcinoma
    • 2974372
    • Nicolaou N, Conlan AA. Cyclophosphamide, doxorubicin and celetin intubation for inoperable oesophageal carcinoma. South African Medical Journal 1982;61(12):428-31. 2974372
    • (1982) South African Medical Journal , vol.61 , Issue.12 , pp. 428-431
    • Nicolaou, N.1    Conlan, A.A.2
  • 33
    • 80053573446 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
    • 2011 2011. 2974374
    • Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 2011 2011;29(30):3968-76. 2974374
    • Journal of Clinical Oncology , vol.29 , Issue.30 , pp. 3968-3976
    • Ohtsu, A.1    Shah, M.A.2    Van Cutsem, E.3    Rha, S.Y.4    Sawaki, A.5    Park, S.R.6
  • 34
    • 84892852727 scopus 로고    scopus 로고
    • Efficacy and safety of S-1 or fluorouracil combined with cisplatin in treatment of advanced esophagus cancer
    • 2974376
    • Pang LN, Wang F, He W, Zhou R, Cao L, Fan QX. Efficacy and safety of S-1 or fluorouracil combined with cisplatin in treatment of advanced esophagus cancer. World Chinese Journal of Digestology 2014;22(3):383-8. 2974376
    • (2014) World Chinese Journal of Digestology , vol.22 , Issue.3 , pp. 383-388
    • Pang, L.N.1    Wang, F.2    He, W.3    Zhou, R.4    Cao, L.5    Fan, Q.X.6
  • 35
    • 19944424421 scopus 로고    scopus 로고
    • Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study
    • 2974378
    • Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Annals of Oncology 2004;15(12):1773-81. 2974378
    • (2004) Annals of Oncology , vol.15 , Issue.12 , pp. 1773-1781
    • Pozzo, C.1    Barone, C.2    Szanto, J.3    Padi, E.4    Peschel, C.5    Bukki, J.6
  • 36
    • 77958496605 scopus 로고    scopus 로고
    • Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
    • 2974380
    • Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Annals of Oncology 2010;21(11):2213-9. 2974380
    • (2010) Annals of Oncology , vol.21 , Issue.11 , pp. 2213-2219
    • Rao, S.1    Starling, N.2    Cunningham, D.3    Sumpter, K.4    Gilligan, D.5    Ruhstaller, T.6
  • 37
    • 84881099408 scopus 로고    scopus 로고
    • Results of docetaxel plus oxaliplatin (DOCOX) (plus or minus) cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised phase 2 study
    • 2974382
    • Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, et al. Results of docetaxel plus oxaliplatin (DOCOX) (plus or minus) cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised phase 2 study. European Journal of Cancer 2013;49(13):2823-31. 2974382
    • (2013) European Journal of Cancer , vol.49 , Issue.13 , pp. 2823-2831
    • Richards, D.1    Kocs, D.M.2    Spira, A.I.3    David McCollum, A.4    Diab, S.5    Hecker, L.I.6
  • 38
    • 0037090686 scopus 로고    scopus 로고
    • Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer
    • 2974384
    • Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of Clinical Oncology 2002;20(8):1996-2004. 2974384
    • (2002) Journal of Clinical Oncology , vol.20 , Issue.8 , pp. 1996-2004
    • Ross, P.1    Nicolson, M.2    Cunningham, D.3    Valle, J.4    Seymour, M.5    Harper, P.6
  • 39
    • 84864371155 scopus 로고    scopus 로고
    • Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
    • 2974386
    • Roy A, Cunningham D, Hawkins R, Sorbye H, Adenis A, Barcelo JR, et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British Journal of Cancer 2012;107(3):435-41. 2974386
    • (2012) British Journal of Cancer , vol.107 , Issue.3 , pp. 435-441
    • Roy, A.1    Cunningham, D.2    Hawkins, R.3    Sorbye, H.4    Adenis, A.5    Barcelo, J.R.6
  • 40
    • 84916196944 scopus 로고    scopus 로고
    • Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
    • 2974388
    • Shen L, Li J, Xu J, Pan H, Dai G, Qin S, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2014;18(1):168-76. 2974388
    • (2014) Gastric Cancer , vol.18 , Issue.1 , pp. 168-176
    • Shen, L.1    Li, J.2    Xu, J.3    Pan, H.4    Dai, G.5    Qin, S.6
  • 41
    • 0036771724 scopus 로고    scopus 로고
    • A muticentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
    • 2974390
    • Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al. A muticentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Annals of Oncology 2002;13(10):1568-75. 2974390
    • (2002) Annals of Oncology , vol.13 , Issue.10 , pp. 1568-1575
    • Tebbutt, N.C.1    Norman, A.2    Cunningham, D.3    Iveson, T.4    Seymour, M.5    Hickish, T.6
  • 42
    • 76349088039 scopus 로고    scopus 로고
    • Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
    • 2974392
    • Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer 2010;102(3):475-81. 2974392
    • (2010) British Journal of Cancer , vol.102 , Issue.3 , pp. 475-481
    • Tebbutt, N.C.1    Cummins, M.M.2    Sourjina, T.3    Strickland, A.4    Van Hazel, G.5    Ganju, V.6
  • 43
    • 80051601789 scopus 로고    scopus 로고
    • Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
    • 2974394
    • Thuss-Patience PC, Kretzschmar A, Dogan Y, Rothmann F, Blau I, Schwaner I, et al. Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. British Journal of Cancer 2011;105(4):505-12. 2974394
    • (2011) British Journal of Cancer , vol.105 , Issue.4 , pp. 505-512
    • Thuss-Patience, P.C.1    Kretzschmar, A.2    Dogan, Y.3    Rothmann, F.4    Blau, I.5    Schwaner, I.6
  • 44
    • 34548258255 scopus 로고    scopus 로고
    • Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group
    • 2974396
    • Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. Journal of Clinical Oncology 2007;25(22):3205-9. 2974396
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.22 , pp. 3205-3209
    • Ajani, J.A.1    Moiseyenko, V.M.2    Tjulandin, S.3    Majlis, A.4    Constenla, M.5    Boni, C.6
  • 45
    • 34548241326 scopus 로고    scopus 로고
    • Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group
    • 2974397
    • Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group. Journal of Clinical Oncology 2007;25(22):3210-6. 2974397
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.22 , pp. 3210-3216
    • Ajani, J.A.1    Moiseyenko, V.M.2    Tjulandin, S.3    Majlis, A.4    Constenla, M.5    Boni, C.6
  • 46
    • 33750949065 scopus 로고    scopus 로고
    • Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group
    • 2974398
    • Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. Journal of Clinical Oncology 2006 Nov;24(31):4991-7. 2974398
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.31 , pp. 4991-4997
    • Van Cutsem, E.1    Moiseyenko, V.M.2    Tjulandin, S.3    Majlis, A.4    Constenla, M.5    Boni, C.6
  • 47
    • 84922571595 scopus 로고    scopus 로고
    • Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
    • 7139598
    • Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Annals of Oncology 2015;26(1):149-56. 7139598
    • (2015) Annals of Oncology , vol.26 , Issue.1 , pp. 149-156
    • Van Cutsem, E.1    Boni, C.2    Tabernero, J.3    Massuti, B.4    Middleton, G.5    Dane, F.6
  • 48
    • 84876992498 scopus 로고    scopus 로고
    • Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    • 2974404
    • Waddell T, Chau I, Cunningham D, Gonzalez D. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncology 2013;14(6):481-9. 2974404
    • (2013) Lancet Oncology , vol.14 , Issue.6 , pp. 481-489
    • Waddell, T.1    Chau, I.2    Cunningham, D.3    Gonzalez, D.4
  • 49
    • 84868295867 scopus 로고    scopus 로고
    • A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3)
    • 2974405
    • Waddell TS, Chau I, Barbachano Y, De Castro DG, Wotherspoon A, Saffery C, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). Journal of Clinical Oncology 2012;30(6):18. 2974405
    • (2012) Journal of Clinical Oncology , vol.30 , Issue.6 , pp. 18
    • Waddell, T.S.1    Chau, I.2    Barbachano, Y.3    De Castro, D.G.4    Wotherspoon, A.5    Saffery, C.6
  • 50
    • 85035130406 scopus 로고    scopus 로고
    • Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma
    • 2974406
    • Waddell TS, Chau I, Peckitt C, Gonzalez D, Wotherspoon A, Patel B, et al. Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma. Journal of Clinical Oncology 2014;32(15):4067. 2974406
    • (2014) Journal of Clinical Oncology , vol.32 , Issue.15 , pp. 4067
    • Waddell, T.S.1    Chau, I.2    Peckitt, C.3    Gonzalez, D.4    Wotherspoon, A.5    Patel, B.6
  • 51
    • 0032921628 scopus 로고    scopus 로고
    • Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial
    • 2974408
    • Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer 1999;80(1-2):269-72. 2974408
    • (1999) British Journal of Cancer , vol.80 , Issue.1-2 , pp. 269-272
    • Waters, J.S.1    Norman, A.2    Cunningham, D.3    Scarffe, J.H.4    Webb, A.5    Harper, P.6
  • 52
    • 0031022803 scopus 로고    scopus 로고
    • Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
    • 2974409
    • Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology 1997;15(1):261-7. 2974409
    • (1997) Journal of Clinical Oncology , vol.15 , Issue.1 , pp. 261-267
    • Webb, A.1    Cunningham, D.2    Scarffe, J.H.3    Harper, P.4    Norman, A.5    Joffe, J.K.6
  • 53
    • 84964688031 scopus 로고    scopus 로고
    • Quality-of-life and performance status results from the phase III RAINBOWstudy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
    • 7139599
    • Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, et al. Quality-of-life and performance status results from the phase III RAINBOWstudy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology 2016;27(4):673-9. 7139599
    • (2016) Annals of Oncology , vol.27 , Issue.4 , pp. 673-679
    • Al-Batran, S.E.1    Van Cutsem, E.2    Oh, S.C.3    Bodoky, G.4    Shimada, Y.5    Hironaka, S.6
  • 54
    • 85016976255 scopus 로고    scopus 로고
    • Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials
    • 7139600
    • Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, et al. Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. Journal of Clinical Oncology 2017 Feb [Epub ahead of print]; Vol. 35, issue 4 Suppl 3. [DOI: 10.1200/JCO.2017.35.4_suppl.3]7139600
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.4
    • Muro, K.1    Cho, J.Y.2    Bodoky, G.3    Goswami, C.4    Chao, Y.5    Dos Santos, L.V.6
  • 55
    • 84959094187 scopus 로고    scopus 로고
    • Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer
    • 7139601
    • Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, et al. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. Journal of Gastroenterology and Hepatology 2016;31(3):581-9. 7139601
    • (2016) Journal of Gastroenterology and Hepatology , vol.31 , Issue.3 , pp. 581-589
    • Muro, K.1    Oh, S.C.2    Shimada, Y.3    Lee, K.W.4    Yen, C.J.5    Chao, Y.6
  • 56
    • 84945587359 scopus 로고    scopus 로고
    • Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
    • 7139602
    • Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 2016;19(3):927-38. 7139602
    • (2016) Gastric Cancer , vol.19 , Issue.3 , pp. 927-938
    • Shitara, K.1    Muro, K.2    Shimada, Y.3    Hironaka, S.4    Sugimoto, N.5    Komatsu, Y.6
  • 57
    • 84908139963 scopus 로고    scopus 로고
    • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    • 2974411
    • Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology 2014;15(11):1224-35. 2974411
    • (2014) Lancet Oncology , vol.15 , Issue.11 , pp. 1224-1235
    • Wilke, H.1    Muro, K.2    Van Cutsem, E.3    Oh, S.C.4    Bodoky, G.5    Shimada, Y.6
  • 59
    • 84892188334 scopus 로고    scopus 로고
    • Nimotuzumab combined with cisplatin and 5-FU in treatment of patients with advanced esophageal squamous cell carcinoma
    • 7139604
    • Xu Z, Chen J, Tao M. Nimotuzumab combined with cisplatin and 5-FU in treatment of patients with advanced esophageal squamous cell carcinoma. Journal of Practical Oncology 2013;28(6):650-3. 7139604
    • (2013) Journal of Practical Oncology , vol.28 , Issue.6 , pp. 650-653
    • Xu, Z.1    Chen, J.2    Tao, M.3
  • 60
    • 78149289601 scopus 로고    scopus 로고
    • Palliative chemotherapy does not improve survival in metastatic esophageal cancer
    • 2974417
    • Adenis A, Penel N, Horn S, Dominguez S, Vanhuyse M, Mirabel X. Palliative chemotherapy does not improve survival in metastatic esophageal cancer. Oncology 2010;79(1-2):46-54. 2974417
    • (2010) Oncology , vol.79 , Issue.1-2 , pp. 46-54
    • Adenis, A.1    Penel, N.2    Horn, S.3    Dominguez, S.4    Vanhuyse, M.5    Mirabel, X.6
  • 61
    • 77952810163 scopus 로고    scopus 로고
    • Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer
    • 2974419
    • Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 2010;116(11):2511-8. 2974419
    • (2010) Cancer , vol.116 , Issue.11 , pp. 2511-2518
    • Al-Batran, S.E.1    Ajani, J.A.2
  • 62
    • 36248982096 scopus 로고    scopus 로고
    • Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer
    • 2974421
    • Albertsson M, Johansson B, Friesland S, Kadar L, Letocha H, Frykholm G, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Medical Oncology (Northwood, London, England) 2007;24(4):407-12. 2974421
    • (2007) Medical Oncology (Northwood, London, England) , vol.24 , Issue.4 , pp. 407-412
    • Albertsson, M.1    Johansson, B.2    Friesland, S.3    Kadar, L.4    Letocha, H.5    Frykholm, G.6
  • 63
    • 71249128928 scopus 로고    scopus 로고
    • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    • 2974423
    • Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncology 2009;10(11):1063-9. 2974423
    • (2009) Lancet Oncology , vol.10 , Issue.11 , pp. 1063-1069
    • Boku, N.1    Yamamoto, S.2    Fukuda, H.3    Shirao, K.4    Doi, T.5    Sawaki, A.6
  • 64
    • 61549123035 scopus 로고    scopus 로고
    • A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma
    • 2974425
    • Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, et al. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemotherapy and Pharmacology 2009;63(5):851-7. 2974425
    • (2009) Cancer Chemotherapy and Pharmacology , vol.63 , Issue.5 , pp. 851-857
    • Brell, J.M.1    Krishnamurthi, S.S.2    Javle, M.3    Saltzman, J.4    Wollner, I.5    Pelley, R.6
  • 65
    • 85020636441 scopus 로고    scopus 로고
    • TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
    • 7139606
    • Burris HA, Kurkjian CD, Hart L, Pant S, Murphy PB, Jones SF, et al. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology 2017;80(2):261-73. 7139606
    • (2017) Cancer Chemotherapy and Pharmacology , vol.80 , Issue.2 , pp. 261-273
    • Burris, H.A.1    Kurkjian, C.D.2    Hart, L.3    Pant, S.4    Murphy, P.B.5    Jones, S.F.6
  • 66
    • 79959576476 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
    • 2974427
    • Cascinu S, Galizia E, Labianca R, Ferrau F, Pucci F, Silva RR, et al. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology 2011;68(1):37-43. 2974427
    • (2011) Cancer Chemotherapy and Pharmacology , vol.68 , Issue.1 , pp. 37-43
    • Cascinu, S.1    Galizia, E.2    Labianca, R.3    Ferrau, F.4    Pucci, F.5    Silva, R.R.6
  • 67
    • 84940099358 scopus 로고    scopus 로고
    • S-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer a randomized, open-label phase 2 trial
    • 7139608
    • Du F, Zheng Z, Shi S, Jiang Z, Qu T, Yuan X, et al. S-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer a randomized, open-label phase 2 trial. Medicine (Baltimore) 2015;94(23):e958. [10.1097/MD.0000000000000958]7139608
    • (2015) Medicine (Baltimore) , vol.94 , Issue.23
    • Du, F.1    Zheng, Z.2    Shi, S.3    Jiang, Z.4    Qu, T.5    Yuan, X.6
  • 68
    • 84969523604 scopus 로고    scopus 로고
    • First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
    • 7139610
    • Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncology 2016;17(7):928-42. 7139610
    • (2016) Lancet Oncology , vol.17 , Issue.7 , pp. 928-942
    • Eichhorst, B.1    Fink, A.M.2    Bahlo, J.3    Busch, R.4    Kovacs, G.5    Maurer, C.6
  • 69
    • 52049103354 scopus 로고    scopus 로고
    • Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
    • 2974429
    • Font A, Salazar R, Maurel J, Taron M, Ramirez JL, Tabernero J, et al. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemotherapy and Pharmacology 2008;62(6):1075-83. 2974429
    • (2008) Cancer Chemotherapy and Pharmacology , vol.62 , Issue.6 , pp. 1075-1083
    • Font, A.1    Salazar, R.2    Maurel, J.3    Taron, M.4    Ramirez, J.L.5    Tabernero, J.6
  • 70
    • 34547756530 scopus 로고    scopus 로고
    • Palliative chemotherapy for recurrent and metastatic esophageal cancer
    • 2974431
    • Grunberger B, Raderer M, Schmidinger M, Hejna M. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Research 2007;27(4 C):2705-14. 2974431
    • (2007) Anticancer Research , vol.27 , Issue.4C , pp. 2705-2714
    • Grunberger, B.1    Raderer, M.2    Schmidinger, M.3    Hejna, M.4
  • 71
    • 77957933128 scopus 로고    scopus 로고
    • Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    • 2974433
    • Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, et al. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010;13(3):155-61. 2974433
    • (2010) Gastric Cancer , vol.13 , Issue.3 , pp. 155-161
    • Gubanski, M.1    Johnsson, A.2    Fernebro, E.3    Kadar, L.4    Karlberg, I.5    Flygare, P.6
  • 72
    • 84895854623 scopus 로고    scopus 로고
    • Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin)
    • 2974435
    • Gubanski M, Glimelius B, Lind PA. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Medical Oncology (Northwood, London) 2014;31(4):906. 2974435
    • (2014) Medical Oncology (Northwood, London) , vol.31 , Issue.4 , pp. 906
    • Gubanski, M.1    Glimelius, B.2    Lind, P.A.3
  • 73
    • 84891372637 scopus 로고    scopus 로고
    • Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial
    • 7139612
    • Hironaka S, Ueda S, Yasui H, Nishina T. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology 2013;31(35):4438-44. 7139612
    • (2013) Journal of Clinical Oncology , vol.31 , Issue.35 , pp. 4438-4444
    • Hironaka, S.1    Ueda, S.2    Yasui, H.3    Nishina, T.4
  • 74
    • 79955462058 scopus 로고    scopus 로고
    • Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis
    • 2974437
    • Horgan AM, Knox JJ, Liu G, Sahi C, Bradbury PA, Leighl NB. Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis. Current Oncology (Toronto) 2011;18(2):e64-e70. 2974437
    • (2011) Current Oncology (Toronto) , vol.18 , Issue.2
    • Horgan, A.M.1    Knox, J.J.2    Liu, G.3    Sahi, C.4    Bradbury, P.A.5    Leighl, N.B.6
  • 75
    • 84883265876 scopus 로고    scopus 로고
    • Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract
    • 2974439
    • Ilhan-Mutlu A, Preusser M, Schoppmann SF, Asari R, Ba-Ssalamah A, Schwameis K, et al. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract. Anticancer Research 2013;33(8):3455-9. 2974439
    • (2013) Anticancer Research , vol.33 , Issue.8 , pp. 3455-3459
    • Ilhan-Mutlu, A.1    Preusser, M.2    Schoppmann, S.F.3    Asari, R.4    Ba-Ssalamah, A.5    Schwameis, K.6
  • 76
    • 73449132552 scopus 로고    scopus 로고
    • Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination
    • 2974441
    • Imazawa M, Kojima T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer 2009;12(3):153-7. 2974441
    • (2009) Gastric Cancer , vol.12 , Issue.3 , pp. 153-157
    • Imazawa, M.1    Kojima, T.2    Boku, N.3    Onozawa, Y.4    Hironaka, S.5    Fukutomi, A.6
  • 77
    • 79955512443 scopus 로고    scopus 로고
    • A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
    • 2011 May 15. 2974443
    • Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer 2011 May 15;117(10):2050-7. 2974443
    • Cancer , vol.117 , Issue.10 , pp. 2050-2057
    • Jeung, H.C.1    Rha, S.Y.2    Im, C.K.3    Shin, S.J.4    Ahn, J.B.5    Yang, W.I.6
  • 78
    • 63749118193 scopus 로고    scopus 로고
    • Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    • 2974445
    • Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of Oncology 2009;20(4):666-73. 2974445
    • (2009) Annals of Oncology , vol.20 , Issue.4 , pp. 666-673
    • Kang, Y.K.1    Kang, W.K.2    Shin, D.B.3    Chen, J.4    Xiong, J.5    Wang, J.6
  • 79
    • 77449140153 scopus 로고    scopus 로고
    • The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
    • 2974447
    • Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009;10:121. 2974447
    • (2009) Trials , vol.10 , pp. 121
    • Kerkar, S.P.1    Kemp, C.D.2    Duffy, A.3    Kammula, U.S.4    Schrump, D.S.5    Kwong, K.F.6
  • 80
    • 84892786410 scopus 로고    scopus 로고
    • A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
    • 2974449
    • Kim YS, Sym SJ, Park SH, Park I, Hong J, Ahn HK, et al. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology 2014;73(1):163-9. 2974449
    • (2014) Cancer Chemotherapy and Pharmacology , vol.73 , Issue.1 , pp. 163-169
    • Kim, Y.S.1    Sym, S.J.2    Park, S.H.3    Park, I.4    Hong, J.5    Ahn, H.K.6
  • 81
    • 73449101494 scopus 로고    scopus 로고
    • Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer
    • 2974451
    • Koizumi W, Tanabe S, Azuma M, Ishido K, Nishimura K, Sasaki T, et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. International Journal of Cancer [Journal International du Cancer] 2010;126(1):162-70. 2974451
    • (2010) International Journal of Cancer [Journal International du Cancer] , vol.126 , Issue.1 , pp. 162-170
    • Koizumi, W.1    Tanabe, S.2    Azuma, M.3    Ishido, K.4    Nishimura, K.5    Sasaki, T.6
  • 82
    • 84895077252 scopus 로고    scopus 로고
    • Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
    • 2974453
    • Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). Journal of Cancer Research and Clinical Oncology 2014;140(2):319-28. 2974453
    • (2014) Journal of Cancer Research and Clinical Oncology , vol.140 , Issue.2 , pp. 319-328
    • Koizumi, W.1    Kim, Y.H.2    Fujii, M.3    Kim, H.K.4    Imamura, H.5    Lee, K.H.6
  • 83
    • 79958270201 scopus 로고    scopus 로고
    • Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
    • 2974455
    • Komatsu Y, Takahashi Y, Kimura Y, Oda H, Tajima Y, Tamura S, et al. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). Anticancer Drugs 2011;22(6):576-83. 2974455
    • (2011) Anticancer Drugs , vol.22 , Issue.6 , pp. 576-583
    • Komatsu, Y.1    Takahashi, Y.2    Kimura, Y.3    Oda, H.4    Tajima, Y.5    Tamura, S.6
  • 85
    • 84954026435 scopus 로고    scopus 로고
    • Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
    • 7139614
    • Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncology 2015;16(13):1324-34. 7139614
    • (2015) Lancet Oncology , vol.16 , Issue.13 , pp. 1324-1334
    • Le Tourneau, C.1    Delord, J.P.2    Gonçalves, A.3    Gavoille, C.4    Dubot, C.5    Isambert, N.6
  • 87
    • 77958146798 scopus 로고    scopus 로고
    • Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer
    • 2974461
    • Lim do H, Park SH, Park KW, Kang JH, Oh SY, Hwang IG, et al. Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. BMC Cancer 2010;10:583. 2974461
    • (2010) BMC Cancer , vol.10 , pp. 583
    • Lim do, H.1    Park, S.H.2    Park, K.W.3    Kang, J.H.4    Oh, S.Y.5    Hwang, I.G.6
  • 88
    • 85022006228 scopus 로고    scopus 로고
    • A randomized phase II study of leucovorin/5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma
    • 7139616
    • Lim SH, Shim YM, Park SH, Kim HK, Choi YS, Ahn MJ, et al. A randomized phase II study of leucovorin/5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma. Cancer Research and Treatment 2017;49(3):816-23. 7139616
    • (2017) Cancer Research and Treatment , vol.49 , Issue.3 , pp. 816-823
    • Lim, S.H.1    Shim, Y.M.2    Park, S.H.3    Kim, H.K.4    Choi, Y.S.5    Ahn, M.J.6
  • 89
    • 63049128125 scopus 로고    scopus 로고
    • A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer
    • 2974463
    • Lissoni P, Rovelli F, Brivio F, Zago R, Colciago M, Messina G, et al. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer. In Vivo 2009;23(1):171-5. 2974463
    • (2009) In Vivo , vol.23 , Issue.1 , pp. 171-175
    • Lissoni, P.1    Rovelli, F.2    Brivio, F.3    Zago, R.4    Colciago, M.5    Messina, G.6
  • 90
    • 84900311800 scopus 로고    scopus 로고
    • S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study
    • 2974465
    • Lu YM, Liu ZC, Zhang J. S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study. Journal of Chemotherapy (Florence) 2014;26(3):159-64. 2974465
    • (2014) Journal of Chemotherapy (Florence) , vol.26 , Issue.3 , pp. 159-164
    • Lu, Y.M.1    Liu, Z.C.2    Zhang, J.3
  • 91
    • 77951000967 scopus 로고    scopus 로고
    • Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study
    • 2974467
    • Lundholm K, Gunnebo L, Korner U, Iresjo BM, Engstrom C, Hyltander A, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 2010;116(8):2044-52. 2974467
    • (2010) Cancer , vol.116 , Issue.8 , pp. 2044-2052
    • Lundholm, K.1    Gunnebo, L.2    Korner, U.3    Iresjo, B.M.4    Engstrom, C.5    Hyltander, A.6
  • 92
    • 77951880092 scopus 로고    scopus 로고
    • Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma
    • 2974469
    • Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, et al. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. Journal of Thoracic Oncology 2010;5(5):713-8. 2974469
    • (2010) Journal of Thoracic Oncology , vol.5 , Issue.5 , pp. 713-718
    • Lustberg, M.B.1    Bekaii-Saab, T.2    Young, D.3    Otterson, G.4    Burak, W.5    Abbas, A.6
  • 93
    • 77149123962 scopus 로고    scopus 로고
    • Economic evaluation of capecitabine use as first line treatment in patients with advanced gastric carcinoma in Portugal
    • 2974471
    • Macedo A, Pereira C, Goncalves J, Sousa C. Economic evaluation of capecitabine use as first line treatment in patients with advanced gastric carcinoma in Portugal. Acta Medica Portuguesa 2009;22(6):827-32. 2974471
    • (2009) Acta Medica Portuguesa , vol.22 , Issue.6 , pp. 827-832
    • Macedo, A.1    Pereira, C.2    Goncalves, J.3    Sousa, C.4
  • 94
    • 81155125099 scopus 로고    scopus 로고
    • A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy
    • 2974473
    • Mizota A, Shitara K, Kondo C, Nomura M, Yokota T, Takahari D, et al. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology (Switzerland) 2011;81(3-4):237-42. 2974473
    • (2011) Oncology (Switzerland) , vol.81 , Issue.3-4 , pp. 237-242
    • Mizota, A.1    Shitara, K.2    Kondo, C.3    Nomura, M.4    Yokota, T.5    Takahari, D.6
  • 95
    • 84984674762 scopus 로고    scopus 로고
    • Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: A randomized, placebo-controlled phase II AIO trial with serum biomarker program
    • Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, et al. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: A randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer 2016;16(1):699. [DOI: 10.1186/s12885-016-2736-9]7139618
    • (2016) BMC Cancer , vol.16 , Issue.1 , pp. 699
    • Moehler, M.1    Gepfner-Tuma, I.2    Maderer, A.3    Thuss-Patience, P.C.4    Ruessel, J.5    Hegewisch-Becker, S.6
  • 96
    • 78149316175 scopus 로고    scopus 로고
    • Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design
    • 2974475
    • Moon YW, Rha SY, Jeung HC, Kim C, Hong MH, Chang H, et al. Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemotherapy and Pharmacology 2010;66(4):797-805. 2974475
    • (2010) Cancer Chemotherapy and Pharmacology , vol.66 , Issue.4 , pp. 797-805
    • Moon, Y.W.1    Rha, S.Y.2    Jeung, H.C.3    Kim, C.4    Hong, M.H.5    Chang, H.6
  • 97
    • 57249084776 scopus 로고    scopus 로고
    • Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution
    • 2974477
    • Nakashima K, Hironaka S, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, et al. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution. Japanese Journal of Clinical Oncology 2008;38(12):810-5. 2974477
    • (2008) Japanese Journal of Clinical Oncology , vol.38 , Issue.12 , pp. 810-815
    • Nakashima, K.1    Hironaka, S.2    Boku, N.3    Onozawa, Y.4    Fukutomi, A.5    Yamazaki, K.6
  • 98
    • 79953025190 scopus 로고    scopus 로고
    • Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
    • 2974479
    • Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011;14(1):72-80. 2974479
    • (2011) Gastric Cancer , vol.14 , Issue.1 , pp. 72-80
    • Narahara, H.1    Iishi, H.2    Imamura, H.3    Tsuburaya, A.4    Chin, K.5    Imamoto, H.6
  • 99
    • 85035123744 scopus 로고    scopus 로고
    • Comparison of efficacy and tolerance of first-line palliative chemotherapy EOX and mDCF regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors
    • 2974543
    • Ochenduszko S, Konopka K, Puskulluoglu M, Urbanczyk K, Budzynski A, Matlok M, et al. Comparison of efficacy and tolerance of first-line palliative chemotherapy EOX and mDCF regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors. Journal of Clinical Oncology 2015;33(3 Suppl):135. 2974543
    • (2015) Journal of Clinical Oncology , vol.33 , Issue.3 , pp. 135
    • Ochenduszko, S.1    Konopka, K.2    Puskulluoglu, M.3    Urbanczyk, K.4    Budzynski, A.5    Matlok, M.6
  • 100
    • 84891371392 scopus 로고    scopus 로고
    • Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study
    • 2974481
    • Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study. Journal of Clinical Oncology 2013;31(31):3935-43. 2974481
    • (2013) Journal of Clinical Oncology , vol.31 , Issue.31 , pp. 3935-3943
    • Ohtsu, A.1    Ajani, J.A.2    Bai, Y.X.3    Bang, Y.J.4    Chung, H.C.5    Pan, H.M.6
  • 101
    • 84979841872 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy with divided-dose docetaxel, cisplatin and fluorouracil for patients with squamous cell carcinoma of the esophagus
    • 7139620
    • Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, et al. Neoadjuvant chemotherapy with divided-dose docetaxel, cisplatin and fluorouracil for patients with squamous cell carcinoma of the esophagus. Anticancer Research 2016;36(2):829-34. 7139620
    • (2016) Anticancer Research , vol.36 , Issue.2 , pp. 829-834
    • Ojima, T.1    Nakamori, M.2    Nakamura, M.3    Katsuda, M.4    Hayata, K.5    Kato, T.6
  • 102
    • 60149088134 scopus 로고    scopus 로고
    • Meta-analysis of the real 2 and ML17032 trials comparing capecitabine with 5-fluorouracil (5-Fu) in advanced oesophago-gastric cancer
    • 2974483
    • Okines AFC, Norman AR, McCloud PI, Kang Y, Cunningham D. Meta-analysis of the real 2 and ML17032 trials comparing capecitabine with 5-fluorouracil (5-Fu) in advanced oesophago-gastric cancer. Annals of Oncology 2008;19(S8):viii169. 2974483
    • (2008) Annals of Oncology , vol.19 , pp. 169
    • Okines, A.F.C.1    Norman, A.R.2    McCloud, P.I.3    Kang, Y.4    Cunningham, D.5
  • 103
    • 77957552916 scopus 로고    scopus 로고
    • Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial
    • 2974485
    • Okines AFC, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. Journal of Clinical Oncology 2010;28(25):3945-50. 2974485
    • (2010) Journal of Clinical Oncology , vol.28 , Issue.25 , pp. 3945-3950
    • Okines, A.F.C.1    Ashley, S.E.2    Cunningham, D.3    Oates, J.4    Turner, A.5    Webb, J.6
  • 104
    • 78649765211 scopus 로고    scopus 로고
    • Rechallenge with platinum plus fluoropyrimidine +/- Epirubicin in patients with oesophagogastric cancer
    • 2974487
    • Okines AFC, Asghar U, Cunningham D, Ashley S, Ashton J, Jackson K, et al. Rechallenge with platinum plus fluoropyrimidine +/- Epirubicin in patients with oesophagogastric cancer. Oncology (Switzerland) 2010;79(1-2):150-8. 2974487
    • (2010) Oncology (Switzerland) , vol.79 , Issue.1-2 , pp. 150-158
    • Okines, A.F.C.1    Asghar, U.2    Cunningham, D.3    Ashley, S.4    Ashton, J.5    Jackson, K.6
  • 105
    • 33646265041 scopus 로고    scopus 로고
    • Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil
    • 2974489
    • Park SH, Lee WK, Chung M, Lee Y, Han SH, Bang SM, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anti-cancer Drugs 2006;17(2):225-9. 2974489
    • (2006) Anti-cancer Drugs , vol.17 , Issue.2 , pp. 225-229
    • Park, S.H.1    Lee, W.K.2    Chung, M.3    Lee, Y.4    Han, S.H.5    Bang, S.M.6
  • 106
    • 84891833821 scopus 로고    scopus 로고
    • Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus
    • 2974491
    • Park JW, Yoon J, Cho CK, Lee YW, Yoo HS. Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus. Chinese Journal of Integrative Medicine 2014;20(1):49-55. 2974491
    • (2014) Chinese Journal of Integrative Medicine , vol.20 , Issue.1 , pp. 49-55
    • Park, J.W.1    Yoon, J.2    Cho, C.K.3    Lee, Y.W.4    Yoo, H.S.5
  • 107
    • 34548243263 scopus 로고    scopus 로고
    • Docetaxel, cisplatin, and fluorouracil; Docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss Group for Clinical Cancer Research
    • 2974493
    • Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, et al. Docetaxel, cisplatin, and fluorouracil; Docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology 2007;25(22):3217-23. 2974493
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.22 , pp. 3217-3223
    • Roth, A.D.1    Fazio, N.2    Stupp, R.3    Falk, S.4    Bernhard, J.5    Saletti, P.6
  • 108
    • 33845626487 scopus 로고    scopus 로고
    • Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
    • 2974495
    • Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 2006;6:274. 2974495
    • (2006) BMC Cancer , vol.6 , pp. 274
    • Sadighi, S.1    Mohagheghi, M.A.2    Montazeri, A.3    Sadighi, Z.4
  • 109
    • 77955716368 scopus 로고    scopus 로고
    • Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis
    • 2974497
    • Sakamoto T, Yasui H, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis. International Journal of Clinical Oncology 2010;15(3):287-93. 2974497
    • (2010) International Journal of Clinical Oncology , vol.15 , Issue.3 , pp. 287-293
    • Sakamoto, T.1    Yasui, H.2    Boku, N.3    Onozawa, Y.4    Hironaka, S.5    Fukutomi, A.6
  • 110
    • 84905566147 scopus 로고    scopus 로고
    • Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - a randomized, phase III study
    • 7139622
    • Satoh T, Xu RH, Chung HC, Sun GP, Doi T. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - a randomized, phase III study. Journal of Clinical Oncology 2014;32(19):2039-49. 7139622
    • (2014) Journal of Clinical Oncology , vol.32 , Issue.19 , pp. 2039-2049
    • Satoh, T.1    Xu, R.H.2    Chung, H.C.3    Sun, G.P.4    Doi, T.5
  • 111
    • 84942115572 scopus 로고    scopus 로고
    • Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
    • 7139624
    • Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer 2015;18(4):824-32. 7139624
    • (2015) Gastric Cancer , vol.18 , Issue.4 , pp. 824-832
    • Satoh, T.1    Lee, K.H.2    Rha, S.Y.3    Sasaki, Y.4    Park, S.H.5    Komatsu, Y.6
  • 112
    • 58149383757 scopus 로고    scopus 로고
    • Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study
    • 2974499
    • Seol YM, Song MK, Choi YJ, Kim GH, Shin HJ, Song GA, et al. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study. Japanese Journal of Clinical Oncology 2009;39(1):43-8. 2974499
    • (2009) Japanese Journal of Clinical Oncology , vol.39 , Issue.1 , pp. 43-48
    • Seol, Y.M.1    Song, M.K.2    Choi, Y.J.3    Kim, G.H.4    Shin, H.J.5    Song, G.A.6
  • 113
    • 84857024667 scopus 로고    scopus 로고
    • Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study
    • 2974501
    • Sgourakis G, Gockel I, Karaliotas C, Moehler M, Schimanski CC, Schmidberger H, et al. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. BMC Cancer 2012;12:70. 2974501
    • (2012) BMC Cancer , vol.12 , pp. 70
    • Sgourakis, G.1    Gockel, I.2    Karaliotas, C.3    Moehler, M.4    Schimanski, C.C.5    Schmidberger, H.6
  • 114
    • 67650424006 scopus 로고    scopus 로고
    • A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer
    • 2974503
    • Shenfine J, McNamee P, Steen N, Bond J, Griffin SM. A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer. American Journal of Gastroenterology 2009;104(7):1674-85. 2974503
    • (2009) American Journal of Gastroenterology , vol.104 , Issue.7 , pp. 1674-1685
    • Shenfine, J.1    McNamee, P.2    Steen, N.3    Bond, J.4    Griffin, S.M.5
  • 115
    • 84885149501 scopus 로고    scopus 로고
    • Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)
    • 2974505
    • Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Japanese Journal of Clinical Oncology 2013;43(10):972-80. 2974505
    • (2013) Japanese Journal of Clinical Oncology , vol.43 , Issue.10 , pp. 972-980
    • Shirao, K.1    Boku, N.2    Yamada, Y.3    Yamaguchi, K.4    Doi, T.5    Goto, M.6
  • 116
    • 79959374724 scopus 로고    scopus 로고
    • Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer
    • 2974507
    • Shitara K, Matsuo K, Mizota A, Kondo C, Nomura M, Takahari D, et al. Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. Gastric Cancer 2011;14(2):155-60. 2974507
    • (2011) Gastric Cancer , vol.14 , Issue.2 , pp. 155-160
    • Shitara, K.1    Matsuo, K.2    Mizota, A.3    Kondo, C.4    Nomura, M.5    Takahari, D.6
  • 117
    • 85021360025 scopus 로고    scopus 로고
    • Adjuvant chemotherapy for chemotherapy-naive advanced gastric cancer patients with oxaliplatin plus tegafur versus oxaliplatin plus S-1
    • 7139626
    • Shu ZB, Ding DY, Li YC. Adjuvant chemotherapy for chemotherapy-naive advanced gastric cancer patients with oxaliplatin plus tegafur versus oxaliplatin plus S-1. International Journal of Clinical and Experimental Medicine 2017;10(6):9322-9. 7139626
    • (2017) International Journal of Clinical and Experimental Medicine , vol.10 , Issue.6 , pp. 9322-9329
    • Shu, Z.B.1    Ding, D.Y.2    Li, Y.C.3
  • 118
    • 84884938232 scopus 로고    scopus 로고
    • Clinical study on efficacy of Aidi injection combined with PT chemotherapy protocol in advanced esophageal cancer patients
    • 2974509
    • Sun J, Sheng ZJ. Clinical study on efficacy of Aidi injection combined with PT chemotherapy protocol in advanced esophageal cancer patients. Cancer Research and Clinic 2013;25(8):547-9. 2974509
    • (2013) Cancer Research and Clinic , vol.25 , Issue.8 , pp. 547-549
    • Sun, J.1    Sheng, Z.J.2
  • 119
    • 77958112709 scopus 로고    scopus 로고
    • Standard first-line chemotherapy for metastatic gastric cancer in Japan has met the global standard: evidence from recent phase III trials
    • 2974511
    • Takashima A, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shimada Y. Standard first-line chemotherapy for metastatic gastric cancer in Japan has met the global standard: evidence from recent phase III trials. Gastrointestinal Cancer Research 2010;3(6):33-8. 2974511
    • (2010) Gastrointestinal Cancer Research , vol.3 , Issue.6 , pp. 33-38
    • Takashima, A.1    Yamada, Y.2    Nakajima, T.E.3    Kato, K.4    Hamaguchi, T.5    Shimada, Y.6
  • 120
    • 78649517442 scopus 로고    scopus 로고
    • Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org)
    • 2974513
    • Tanaka T, Fujita H, Matono S, Nagano T, Nishimura K, Murata K, et al. Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org). Diseases of the Esophagus 2010;23(8):646-51. 2974513
    • (2010) Diseases of the Esophagus , vol.23 , Issue.8 , pp. 646-651
    • Tanaka, T.1    Fujita, H.2    Matono, S.3    Nagano, T.4    Nishimura, K.5    Murata, K.6
  • 121
    • 20044393181 scopus 로고    scopus 로고
    • Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study
    • 2974515
    • Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. Journal of Clinical Oncology 2005;23(3):494-501. 2974515
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.3 , pp. 494-501
    • Thuss-Patience, P.C.1    Kretzschmar, A.2    Repp, M.3    Kingreen, D.4    Hennesser, D.5    Micheel, S.6
  • 122
    • 79954529931 scopus 로고    scopus 로고
    • Systematic review: quality of life after treatment for upper gastrointestinal cancer
    • 2974517
    • Whistance RN, Blazeby JM. Systematic review: quality of life after treatment for upper gastrointestinal cancer. Current Opinion in Supportive and Palliative Care 2011;5(1):37-46. 2974517
    • (2011) Current Opinion in Supportive and Palliative Care , vol.5 , Issue.1 , pp. 37-46
    • Whistance, R.N.1    Blazeby, J.M.2
  • 123
    • 84883424576 scopus 로고    scopus 로고
    • Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer
    • 7139628
    • Xu Y, Zhao AG, Li ZY, Zhao G, Cai Y, Zhu XH, et al. Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer. Integrative Cancer Therapies 2013;12(5):414-22. 7139628
    • (2013) Integrative Cancer Therapies , vol.12 , Issue.5 , pp. 414-422
    • Xu, Y.1    Zhao, A.G.2    Li, Z.Y.3    Zhao, G.4    Cai, Y.5    Zhu, X.H.6
  • 124
    • 84924176167 scopus 로고    scopus 로고
    • Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer
    • 2974521
    • Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Annals of Oncology 2015;26(1):141-8. 2974521
    • (2015) Annals of Oncology , vol.26 , Issue.1 , pp. 141-148
    • Yamada, Y.1    Higuchi, K.2    Nishikawa, K.3    Gotoh, M.4    Fuse, N.5    Sugimoto, N.6
  • 125
    • 43449089197 scopus 로고    scopus 로고
    • A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum
    • 2974523
    • Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, et al. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum. International Journal of Clinical Oncology 2008;13(2):150-5. 2974523
    • (2008) International Journal of Clinical Oncology , vol.13 , Issue.2 , pp. 150-155
    • Yamazaki, K.1    Hironaka, S.2    Boku, N.3    Yasui, H.4    Fukutomi, A.5    Yoshino, T.6
  • 126
    • 77956200533 scopus 로고    scopus 로고
    • Clinical study of paclitaxel plus nedaplatin versus paclitaxel plus cisplatin in treatment of patients with advanced esophageal carcinoma
    • 2974525
    • Yu J, Wang BH, Zhang XZ. Clinical study of paclitaxel plus nedaplatin versus paclitaxel plus cisplatin in treatment of patients with advanced esophageal carcinoma. Chinese Journal of Cancer Prevention and Treatment 2010;17(9):693-5. 2974525
    • (2010) Chinese Journal of Cancer Prevention and Treatment , vol.17 , Issue.9 , pp. 693-695
    • Yu, J.1    Wang, B.H.2    Zhang, X.Z.3
  • 127
    • 77349105561 scopus 로고    scopus 로고
    • A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
    • 2974527
    • Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. European Journal of Cancer 2010;46(5):885-91. 2974527
    • (2010) European Journal of Cancer , vol.46 , Issue.5 , pp. 885-891
    • Yun, J.1    Lee, J.2    Park, S.H.3    Park, J.O.4    Park, Y.S.5    Lim, H.Y.6
  • 128
    • 38049089933 scopus 로고    scopus 로고
    • Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors
    • 2974529
    • Zhang P, Feng FY, Wu LY, Hu Y, Liu JW, Gao YJ, et al. Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors. Zhonghua Zhong Liu Za Zhi 2006;28(3):230-4. 2974529
    • (2006) Zhonghua Zhong Liu Za Zhi , vol.28 , Issue.3 , pp. 230-234
    • Zhang, P.1    Feng, F.Y.2    Wu, L.Y.3    Hu, Y.4    Liu, J.W.5    Gao, Y.J.6
  • 129
    • 85029883343 scopus 로고    scopus 로고
    • A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer
    • 7139630
    • Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, et al. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Annals of Oncology 2017;28(9):2142-8. 7139630
    • (2017) Annals of Oncology , vol.28 , Issue.9 , pp. 2142-2148
    • Ajani, J.A.1    Abramov, M.2    Bondarenko, I.3    Shparyk, Y.4    Gorbunova, V.5    Hontsa, A.6
  • 130
    • 85021142087 scopus 로고    scopus 로고
    • A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
    • Al-Batran SE, Riera-Knorrenschild J, Pauligk C, Goetze TO, Hegewisch-Becker S, Seraphin J, et al. A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Journal of Clinical Oncology 2017;35(4 Suppl):4. [DOI: 10.1200/JCO.2017.35.4_suppl.4]7139632
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.4 , pp. 4
    • Al-Batran, S.E.1    Riera-Knorrenschild, J.2    Pauligk, C.3    Goetze, T.O.4    Hegewisch-Becker, S.5    Seraphin, J.6
  • 131
    • 85032002887 scopus 로고    scopus 로고
    • Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer
    • 7139634
    • Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, et al. Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clinical Cancer Research 2017;23(19):5671-8. 7139634
    • (2017) Clinical Cancer Research , vol.23 , Issue.19 , pp. 5671-5678
    • Bang, Y.J.1    Cho, J.Y.2    Kim, Y.H.3    Kim, J.W.4    Di Bartolomeo, M.5    Ajani, J.A.6
  • 132
    • 85028576805 scopus 로고    scopus 로고
    • Preliminary results of a randomized phase II study: Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence
    • 2974531
    • Bi F, Li Q, Zhou C, Yu J, Cai X, Qiu M, et al. Preliminary results of a randomized phase II study: Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence. Journal of Clinical Oncology 2011;29(15):Supplement. 2974531
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.15
    • Bi, F.1    Li, Q.2    Zhou, C.3    Yu, J.4    Cai, X.5    Qiu, M.6
  • 133
    • 84887565114 scopus 로고    scopus 로고
    • Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led phase II randomized study
    • 2974533
    • Cohen DJ, Christos PJ, Kindler HL, Catenacci DVT, Bekaii-Saab TB, Tahiri S, et al. Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led phase II randomized study. Journal of Clinical Oncology 2013;31(15):4011. 2974533
    • (2013) Journal of Clinical Oncology , vol.31 , Issue.15 , pp. 4011
    • Cohen, D.J.1    Christos, P.J.2    Kindler, H.L.3    Catenacci, D.V.T.4    Bekaii-Saab, T.B.5    Tahiri, S.6
  • 134
    • 85018621226 scopus 로고    scopus 로고
    • Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC)
    • 7139636
    • Denlinger CS, Maqueda MA, Watkins DJ, Sym SJ, Bendell JC, Park SH, et al. Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC). Journal of Clinical Oncology 2016;34(15 Suppl):4043. 7139636
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.15 , pp. 4043
    • Denlinger, C.S.1    Maqueda, M.A.2    Watkins, D.J.3    Sym, S.J.4    Bendell, J.C.5    Park, S.H.6
  • 135
    • 84981711242 scopus 로고    scopus 로고
    • CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers
    • 7139638
    • Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. Journal of Clinical Oncology 2016;34(23):2736-42. 7139638
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.23 , pp. 2736-2742
    • Enzinger, P.C.1    Burtness, B.A.2    Niedzwiecki, D.3    Ye, X.4    Douglas, K.5    Ilson, D.H.6
  • 136
    • 85009775887 scopus 로고    scopus 로고
    • A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
    • 7139640
    • Hall PS, Lord SR, Collinson M, Marshall H, Jones M, Lowe C, et al. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). British Journal of Cancer 2017;116(4):472-8. 7139640
    • (2017) British Journal of Cancer , vol.116 , Issue.4 , pp. 472-478
    • Hall, P.S.1    Lord, S.R.2    Collinson, M.3    Marshall, H.4    Jones, M.5    Lowe, C.6
  • 137
    • 84958818670 scopus 로고    scopus 로고
    • Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC - A randomized phase III trial
    • 7139642
    • Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC - A randomized phase III trial. Journal of Clinical Oncology 2016;34(5):443-51. 7139642
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.5 , pp. 443-451
    • Hecht, J.R.1    Bang, Y.J.2    Qin, S.K.3    Chung, H.C.4    Xu, J.M.5    Park, J.O.6
  • 138
    • 85084273370 scopus 로고    scopus 로고
    • Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis
    • LBA27
    • Huang J, Liu Y, Dai S, Lu P, Ba Y, Wu L, et al. Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis. Annals of Oncology 2016;27(6 Suppl):LBA27. [DOI: 10.1093/annonc/mdw435.18]7139644
    • (2016) Annals of Oncology , vol.27 , Issue.6
    • Huang, J.1    Liu, Y.2    Dai, S.3    Lu, P.4    Ba, Y.5    Wu, L.6
  • 139
    • 85032565953 scopus 로고    scopus 로고
    • A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201
    • 7139646
    • Iqbal S, McDonough S, Lenz HJ, Ilson DH, Burtness B, Nangia CS, et al. A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201. Journal of Clinical Oncology 2017;35(15 Suppl):4009. 7139646
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.15 , pp. 4009
    • Iqbal, S.1    McDonough, S.2    Lenz, H.J.3    Ilson, D.H.4    Burtness, B.5    Nangia, C.S.6
  • 140
    • 85006292884 scopus 로고    scopus 로고
    • CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC)
    • 7139648
    • Janjigian YY, Bendell JC, Calvo E, Kim JW, Ascierto PA, Sharma P, et al. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). Journal of Clinical Oncology 2016;34(14 Suppl):4010. 7139648
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.14 , pp. 4010
    • Janjigian, Y.Y.1    Bendell, J.C.2    Calvo, E.3    Kim, J.W.4    Ascierto, P.A.5    Sharma, P.6
  • 141
    • 85018495296 scopus 로고    scopus 로고
    • Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
    • 7139650
    • Kang YK, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. Journal of Clinical Oncology 2017;35(4 Suppl):2. 7139650
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.4 , pp. 2
    • Kang, Y.K.1    Satoh, T.2    Ryu, M.H.3    Chao, Y.4    Kato, K.5    Chung, H.C.6
  • 142
    • 85035114048 scopus 로고    scopus 로고
    • Phase III trial of a 3-weekly vs. 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study
    • 2974537
    • Lee KH, Baba E, Ryu MH, Boku N, Park YI, Hyodo I, et al. Phase III trial of a 3-weekly vs. 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study. European Journal of Cancer 2013;49(14):S614-5. 2974537
    • (2013) European Journal of Cancer , vol.49 , Issue.14 , pp. S614-S615
    • Lee, K.H.1    Baba, E.2    Ryu, M.H.3    Boku, N.4    Park, Y.I.5    Hyodo, I.6
  • 143
    • 84944407145 scopus 로고    scopus 로고
    • Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study
    • 7139652
    • Lee SJ, Kim S, Kim M, Lee J, Park YH, Im Y-H, et al. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study. BMC Cancer 2015;15(1):693. 7139652
    • (2015) BMC Cancer , vol.15 , Issue.1 , pp. 693
    • Lee, S.J.1    Kim, S.2    Kim, M.3    Lee, J.4    Park, Y.H.5    Im, Y.-H.6
  • 144
    • 84946560857 scopus 로고    scopus 로고
    • S-1 plus Cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: A pilot study
    • 7139654
    • Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, et al. S-1 plus Cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: A pilot study. Oncotarget 2015;6(33):35107-15. 7139654
    • (2015) Oncotarget , vol.6 , Issue.33 , pp. 35107-35115
    • Li, Y.H.1    Qiu, M.Z.2    Xu, J.M.3    Sun, G.P.4    Lu, H.S.5    Liu, Y.P.6
  • 145
    • 84968894979 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
    • 7139656
    • Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. Journal of Clinical Oncology 2016;34(13):1448-54. 7139656
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.13 , pp. 1448-1454
    • Li, J.1    Qin, S.2    Xu, J.3    Xiong, J.4    Wu, C.5    Bai, Y.6
  • 146
    • 85014221633 scopus 로고    scopus 로고
    • Clinical efficacy and safety of nedaplatin combined with paclitaxel liposome in treatment of advanced esophageal cancer
    • 7139658
    • Li K, Liu J. Clinical efficacy and safety of nedaplatin combined with paclitaxel liposome in treatment of advanced esophageal cancer. Cancer Research and Clinic 2016;28(11):748-51. [10.3760/cma.j.issn.1006-9801.2016.11.007]7139658
    • (2016) Cancer Research and Clinic , vol.28 , Issue.11 , pp. 748-751
    • Li, K.1    Liu, J.2
  • 147
    • 84995603559 scopus 로고    scopus 로고
    • Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer
    • 7139660
    • Liu Y, Ren R, Yuan L, Xu S, Yao Z, Qiao L, et al. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. American Journal of Cancer Research 2016;6(10):2345-50. 7139660
    • (2016) American Journal of Cancer Research , vol.6 , Issue.10 , pp. 2345-2350
    • Liu, Y.1    Ren, R.2    Yuan, L.3    Xu, S.4    Yao, Z.5    Qiao, L.6
  • 148
    • 85035107554 scopus 로고    scopus 로고
    • Randomized phase II study of cisplatin and high dose 5-fluorouracil/leucovorin or paclitaxel and high-dose 5-fluorouracil/leucovorin in locally advanced or metastatic gastric cancer and adenocarcinomas of the gastrooesophageal junction
    • 2974539
    • Luelmo S, Polee M, Van Bochove A, Pruijt H, Ouwerkerk J, Sleeboom H, et al. Randomized phase II study of cisplatin and high dose 5-fluorouracil/leucovorin or paclitaxel and high-dose 5-fluorouracil/leucovorin in locally advanced or metastatic gastric cancer and adenocarcinomas of the gastrooesophageal junction. Annals of Oncology 2008;19(S8):viii173-viii174. 2974539
    • (2008) Annals of Oncology , vol.19 , pp. 173-174
    • Luelmo, S.1    Polee, M.2    Van Bochove, A.3    Pruijt, H.4    Ouwerkerk, J.5    Sleeboom, H.6
  • 149
    • 84897444269 scopus 로고    scopus 로고
    • FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric AIO phase II trial
    • 2974541
    • Moehler MH, Thuss-Patience PC, Schmoll HJ, Hegewisch-Becker S, Wilke H, Al-Batran SE, et al. FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric AIO phase II trial. Journal of Clinical Oncology 2013;31(15 Suppl):4086. 2974541
    • (2013) Journal of Clinical Oncology , vol.31 , Issue.15 , pp. 4086
    • Moehler, M.H.1    Thuss-Patience, P.C.2    Schmoll, H.J.3    Hegewisch-Becker, S.4    Wilke, H.5    Al-Batran, S.E.6
  • 150
    • 85010012510 scopus 로고    scopus 로고
    • A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer
    • 7139662
    • Moehler MH, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, et al. A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer. Journal of Clinical Oncology 2016;34(Suppl):4011. 7139662
    • (2016) Journal of Clinical Oncology , vol.34 , pp. 4011
    • Moehler, M.H.1    Cho, J.Y.2    Kim, Y.H.3    Kim, J.W.4    Di Bartolomeo, M.5    Ajani, J.A.6
  • 151
    • 85035116633 scopus 로고    scopus 로고
    • Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER)
    • 7139664
    • Moehler MH, Thuss-Patience PC, Brenner B, Longo F, Meiler J, Ettrich TJ, et al. Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER). Journal of Clinical Oncology 2017;35(15 Suppl):4011. 7139664
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.15 , pp. 4011
    • Moehler, M.H.1    Thuss-Patience, P.C.2    Brenner, B.3    Longo, F.4    Meiler, J.5    Ettrich, T.J.6
  • 152
    • 84951568141 scopus 로고    scopus 로고
    • INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)-Final overall and subgroup results
    • 2974545
    • Pavlakis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang YK, Bang YJ, et al. INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)-Final overall and subgroup results. Journal of Clinical Oncology 2015;33(15 Suppl):4003. 2974545
    • (2015) Journal of Clinical Oncology , vol.33 , Issue.15 , pp. 4003
    • Pavlakis, N.1    Sjoquist, K.M.2    Tsobanis, E.3    Martin, A.J.4    Kang, Y.K.5    Bang, Y.J.6
  • 153
    • 85035079407 scopus 로고    scopus 로고
    • Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study
    • 7139666
    • Ryu MH, Park YI, Chung IJ, Lee KW, Oh HS, Lee KH, et al. Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study. Journal of Clinical Oncology 2016;34(15 Suppl):4015. 7139666
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.15 , pp. 4015
    • Ryu, M.H.1    Park, Y.I.2    Chung, I.J.3    Lee, K.W.4    Oh, H.S.5    Lee, K.H.6
  • 154
    • 84955600552 scopus 로고    scopus 로고
    • IMAB362 plus zoledronic acid (ZA) and interleukin2 (IL2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial
    • 7139668
    • Sahin U, Al-Batran SE, Hozaeel W, Zvirbule Z, Freiberg-Richter J, Lordick F, et al. IMAB362 plus zoledronic acid (ZA) and interleukin2 (IL2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial. Journal of Clinical Oncology 2015 [Epub ahead of print]; Vol. 33, issue 15 Suppl. [DOI: 10.1200/jco.2015.33.15_suppl.e15079]7139668
    • (2015) Journal of Clinical Oncology , vol.33 , Issue.15
    • Sahin, U.1    Al-Batran, S.E.2    Hozaeel, W.3    Zvirbule, Z.4    Freiberg-Richter, J.5    Lordick, F.6
  • 155
    • 85019994949 scopus 로고    scopus 로고
    • Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma
    • Oct 11 [Epub ahead of print], 7139670
    • Schuler M, Al-Batran SE, Zvirbule Z, Manikhas G, Lordick F, Rusyn A, et al. Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology 2016 Oct 11 [Epub ahead of print]; Vol. 27, issue 6 Suppl. [DOI: 10.1093/annonc/mdw371.06]7139670
    • (2016) Annals of Oncology , vol.27 , Issue.6
    • Schuler, M.1    Al-Batran, S.E.2    Zvirbule, Z.3    Manikhas, G.4    Lordick, F.5    Rusyn, A.6
  • 156
    • 84948456752 scopus 로고    scopus 로고
    • Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: A study of the US gastric cancer consortium
    • 7139672
    • Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: A study of the US gastric cancer consortium. Journal of Clinical Oncology 2015;33(33):3874-9. 7139672
    • (2015) Journal of Clinical Oncology , vol.33 , Issue.33 , pp. 3874-3879
    • Shah, M.A.1    Janjigian, Y.Y.2    Stoller, R.3    Shibata, S.4    Kemeny, M.5    Krishnamurthi, S.6
  • 157
    • 84988025815 scopus 로고    scopus 로고
    • A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced Adenocarcinoma of the stomach and Gastroesophageal junction
    • 7139674
    • Shah MA, Cho JY, Tan IB, Tebbutt NC, Yen CJ, Kang A, et al. A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced Adenocarcinoma of the stomach and Gastroesophageal junction. Oncologist 2016;21(9):1085-90. 7139674
    • (2016) Oncologist , vol.21 , Issue.9 , pp. 1085-1090
    • Shah, M.A.1    Cho, J.Y.2    Tan, I.B.3    Tebbutt, N.C.4    Yen, C.J.5    Kang, A.6
  • 158
    • 85014731413 scopus 로고    scopus 로고
    • Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: The METGastric Randomized Clinical Trial
    • 7139676
    • Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncology 2017;3(5):620-7. 7139676
    • (2017) JAMA Oncology , vol.3 , Issue.5 , pp. 620-627
    • Shah, M.A.1    Bang, Y.J.2    Lordick, F.3    Alsina, M.4    Chen, M.5    Hack, S.P.6
  • 159
    • 82655178217 scopus 로고    scopus 로고
    • Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): combined U.S. experience
    • 2974547
    • Smyth EC, Enzinger PC, Li J, Vincitore M, Lacy J, El-Rayes BF, et al. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): combined U.S. experience. Journal of Clinical Oncology 2011;29(15 Suppl):4056. 2974547
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.15 , pp. 4056
    • Smyth, E.C.1    Enzinger, P.C.2    Li, J.3    Vincitore, M.4    Lacy, J.5    El-Rayes, B.F.6
  • 160
    • 85035140894 scopus 로고    scopus 로고
    • Effect of S-1 maintenance chemotherapy following first-line regimen in patients with advanced esophageal cancer
    • 7139678
    • Song L. Effect of S-1 maintenance chemotherapy following first-line regimen in patients with advanced esophageal cancer. Diseases of the Esophagus 2016;29:130A-131A. 7139678
    • (2016) Diseases of the Esophagus , vol.29 , pp. 130A-131A
    • Song, L.1
  • 161
    • 84923111270 scopus 로고    scopus 로고
    • Final results of AGITG ATTAX 3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer
    • 2974549
    • Tebbutt NC, Price TJ, Sjoquist KM, Veillard AS, Hall M, Ferraro DA, et al. Final results of AGITG ATTAX 3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer. Journal of Clinical Oncology 2013;31(15 Suppl):4081. 2974549
    • (2013) Journal of Clinical Oncology , vol.31 , Issue.15 , pp. 4081
    • Tebbutt, N.C.1    Price, T.J.2    Sjoquist, K.M.3    Veillard, A.S.4    Hall, M.5    Ferraro, D.A.6
  • 162
    • 84959369848 scopus 로고    scopus 로고
    • Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
    • 7139680
    • Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, et al. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer 2016;114(5):505-9. 7139680
    • (2016) British Journal of Cancer , vol.114 , Issue.5 , pp. 505-509
    • Tebbutt, N.C.1    Price, T.J.2    Ferraro, D.A.3    Wong, N.4    Veillard, A.S.5    Hall, M.6
  • 163
    • 84977632818 scopus 로고    scopus 로고
    • Pazopanib and 5-FU/ oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie)
    • 7139682
    • Thuss-Patience PC, Al-Batran SE, Siveke JT, Homann N, Malfertheiner P, Glaeser D, et al. Pazopanib and 5-FU/ oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie). Journal of Clinical Oncology 2015;33(15 Suppl):4033. 7139682
    • (2015) Journal of Clinical Oncology , vol.33 , Issue.15 , pp. 4033
    • Thuss-Patience, P.C.1    Al-Batran, S.E.2    Siveke, J.T.3    Homann, N.4    Malfertheiner, P.5    Glaeser, D.6
  • 164
    • 85017152115 scopus 로고    scopus 로고
    • Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
    • 7139684
    • Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology 2017;18(5):640-53. 7139684
    • (2017) Lancet Oncology , vol.18 , Issue.5 , pp. 640-653
    • Thuss-Patience, P.C.1    Shah, M.A.2    Ohtsu, A.3    Van Cutsem, E.4    Ajani, J.A.5    Castro, H.6
  • 165
    • 84970044407 scopus 로고    scopus 로고
    • Clinical effects of Zhisheng capsule combined with chemotherapy on patients with middle or advanced stage oesophageal cancer
    • 7139686
    • Wang X-Q, Yang F. Clinical effects of Zhisheng capsule combined with chemotherapy on patients with middle or advanced stage oesophageal cancer. Drugs & Clinic 2010;25(4):297-9. 7139686
    • (2010) Drugs & Clinic , vol.25 , Issue.4 , pp. 297-299
    • Wang, X.-Q.1    Yang, F.2
  • 166
    • 84951568174 scopus 로고    scopus 로고
    • Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
    • 7139688
    • Wang JW, Xu RH, Li J, Bai YX, Liu TS, Jiao SC, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer 2016;19(1):234-44. 7139688
    • (2016) Gastric Cancer , vol.19 , Issue.1 , pp. 234-244
    • Wang, J.W.1    Xu, R.H.2    Li, J.3    Bai, Y.X.4    Liu, T.S.5    Jiao, S.C.6
  • 168
    • 84969977082 scopus 로고    scopus 로고
    • Clinical observation on Aidi injection supplemental to chemotherapy in treatment of advanced oesophageal carcinoma
    • 7139692
    • Wu J, Long GX. Clinical observation on Aidi injection supplemental to chemotherapy in treatment of advanced oesophageal carcinoma. Journal of Internal Intensive Medicine 2013;19(2):100-15. 7139692
    • (2013) Journal of Internal Intensive Medicine , vol.19 , Issue.2 , pp. 100-115
    • Wu, J.1    Long, G.X.2
  • 169
    • 85035085340 scopus 로고    scopus 로고
    • The efficacy and adverse reaction of docetaxel combined with oxaliplatin in the treatment of advanced esophageal cancer
    • 7139694
    • Xie C, Shi Y, Zhu Z, Li Z, Yu X. The efficacy and adverse reaction of docetaxel combined with oxaliplatin in the treatment of advanced esophageal cancer. Anti-Tumor Pharma 2016;6(5):361-5. 7139694
    • (2016) Anti-Tumor Pharma , vol.6 , Issue.5 , pp. 361-365
    • Xie, C.1    Shi, Y.2    Zhu, Z.3    Li, Z.4    Yu, X.5
  • 170
    • 85035088197 scopus 로고    scopus 로고
    • Safety and tolerability data from a phase II study of AUY922 compared with chemotherapy in patients with advanced gastric cancer
    • 2974551
    • Yeh KH, Chen JS, Sobrero A, Singhal N, De Dosso S, Kang YK, et al. Safety and tolerability data from a phase II study of AUY922 compared with chemotherapy in patients with advanced gastric cancer. Annals of Oncology 2012;23(4):118. 2974551
    • (2012) Annals of Oncology , vol.23 , Issue.4 , pp. 118
    • Yeh, K.H.1    Chen, J.S.2    Sobrero, A.3    Singhal, N.4    De Dosso, S.5    Kang, Y.K.6
  • 171
    • 85030256768 scopus 로고    scopus 로고
    • Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
    • 7139696
    • Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Annals of Oncology 2016;27(12):2196-203. 7139696
    • (2016) Annals of Oncology , vol.27 , Issue.12 , pp. 2196-2203
    • Yoon, H.H.1    Bendell, J.C.2    Braiteh, F.S.3    Firdaus, I.4    Philip, P.A.5    Cohn, A.L.6
  • 172
    • 85035151642 scopus 로고    scopus 로고
    • Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial
    • 7139698
    • Zaanan A, Bennouna J, Hiret S, Douillard JY, Bouche O, Tougeron D, et al. Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial. Journal of Clinical Oncology 2015;33(15 Suppl):4027. 7139698
    • (2015) Journal of Clinical Oncology , vol.33 , Issue.15 , pp. 4027
    • Zaanan, A.1    Bennouna, J.2    Hiret, S.3    Douillard, J.Y.4    Bouche, O.5    Tougeron, D.6
  • 173
    • 85035090122 scopus 로고    scopus 로고
    • Comparison of efficacy and safety of paclitaxel and capecitabine followed by capecitabine as maintenance therapy versus cisplatin and capecitabine therapy for advanced gastric cancer: A multicentre, randomised, active-controlled phase III study
    • Zhang X, Shen L, Lu Z, Liu W, Liu T, Hu B, et al. Comparison of efficacy and safety of paclitaxel and capecitabine followed by capecitabine as maintenance therapy versus cisplatin and capecitabine therapy for advanced gastric cancer: A multicentre, randomised, active-controlled phase III study. Annals of Oncology 2015;26(9 Suppl):ix44. [DOI: 10.1093/annonc/mdv523.05]7139700
    • (2015) Annals of Oncology , vol.26 , Issue.9 , pp. 44
    • Zhang, X.1    Shen, L.2    Lu, Z.3    Liu, W.4    Liu, T.5    Hu, B.6
  • 174
    • 84988345858 scopus 로고    scopus 로고
    • Clinical observation of S-l in the maintenance treatment of advanced esophageal cancer
    • 7139702
    • Zhou Y, Liu C, Tang Y, Wang S. Clinical observation of S-l in the maintenance treatment of advanced esophageal cancer. Cancer Research and Clinic 2016;28(7):452-4. 7139702
    • (2016) Cancer Research and Clinic , vol.28 , Issue.7 , pp. 452-454
    • Zhou, Y.1    Liu, C.2    Tang, Y.3    Wang, S.4
  • 175
    • 85035135948 scopus 로고    scopus 로고
    • FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-ONcology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC
    • 7139704
    • Aanur P, Gutierrez M, Kelly RJ, Ajani JA, Ku GY, Denlinger CS, et al. FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-ONcology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC. Journal of Clinical Oncology 2017 [Epub ahead of print]; Vol. 35, issue 15 Suppl. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS4137]7139704
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.15
    • Aanur, P.1    Gutierrez, M.2    Kelly, R.J.3    Ajani, J.A.4    Ku, G.Y.5    Denlinger, C.S.6
  • 176
    • 84993927811 scopus 로고    scopus 로고
    • JAGUAR: a randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma
    • 2974553
    • Bang YJ, Kang YK, Alsina M, Wainberg ZA, Chau I, Zhu J, et al. JAGUAR: a randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology 2014;32(15 Suppl):TPS4147. 2974553
    • (2014) Journal of Clinical Oncology , vol.32 , Issue.15 , pp. 4147
    • Bang, Y.J.1    Kang, Y.K.2    Alsina, M.3    Wainberg, Z.A.4    Chau, I.5    Zhu, J.6
  • 177
    • 85036497908 scopus 로고    scopus 로고
    • A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    • 7139706
    • Bendell JC, Starodub A, Huang X, Maltzman JD, Wainberg ZA, Shah MA. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology 2017 [Epub ahead of print]; Vol. 35, issue 15 Suppl. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS4139]7139706
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.15
    • Bendell, J.C.1    Starodub, A.2    Huang, X.3    Maltzman, J.D.4    Wainberg, Z.A.5    Shah, M.A.6
  • 178
    • 84982867393 scopus 로고    scopus 로고
    • PLATFORM: Planning treatment of oesophago-gastric (OG) cancer randomised maintenance therapy trial
    • NCT02678182]7139708
    • Cafferkey C, Chau I, Thistlethwaite F, Petty RD, Starling N, Watkins D, et al. PLATFORM: Planning treatment of oesophago-gastric (OG) cancer randomised maintenance therapy trial. Journal of Clinical Oncology 2016 [Epub ahead of print]; Vol. 34, issue 4 Suppl. [DOI: 10.1200/jco.2016.34.4_suppl.tps187; NCT02678182]7139708
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.4
    • Cafferkey, C.1    Chau, I.2    Thistlethwaite, F.3    Petty, R.D.4    Starling, N.5    Watkins, D.6
  • 179
    • 85035085984 scopus 로고    scopus 로고
    • A randomized clinical trial of best supportive care compared with best supportive care with chemotherapy in advanced unresectable or metastatic esophageal cancer
    • (first received 1 January 2016). 7139710
    • CTRI/2016/01/006474. Palliative chemotherapy in esophageal cancer for survival [A randomized clinical trial of best supportive care compared with best supportive care with chemotherapy in advanced unresectable or metastatic esophageal cancer]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13694 (first received 1 January 2016). 7139710
  • 180
    • 85034624444 scopus 로고    scopus 로고
    • KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma
    • 7139712
    • Doi T, Bennouna J, Shen L, Enzinger PC, Wang R, Csiki I, et al. KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma. Journal of Clinical Oncology 2016 [Epub ahead of print]; Vol. 34, issue 15 Suppl. [DOI: 10.1200/JCO.2016.34.15_suppl.TPS4140]7139712
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.15
    • Doi, T.1    Bennouna, J.2    Shen, L.3    Enzinger, P.C.4    Wang, R.5    Csiki, I.6
  • 181
    • 85016976255 scopus 로고    scopus 로고
    • ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum
    • 7139714
    • Esaki T, Makiyama A, Kashiwada T, Hosokawa A, Kawada J, Moriwaki T, et al. ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology 2017 [Epub ahead of print]; Vol. 35, issue 4 Suppl. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218]7139714
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.4
    • Esaki, T.1    Makiyama, A.2    Kashiwada, T.3    Hosokawa, A.4    Kawada, J.5    Moriwaki, T.6
  • 182
    • 85035126545 scopus 로고    scopus 로고
    • A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in subjects with unresectable advanced, recurrent or metastatic previously untreated esophageal squamous cell carcinoma
    • (first received 17 October 2016). 7139716
    • EUCTR 2016-001514-20. A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in subjects with unresectable advanced, recurrent or metastatic previously untreated esophageal squamous cell carcinoma. clinicaltrialsregister.eu/ctr-search/trial/2016-001514-20 (first received 17 October 2016). 7139716
  • 183
    • 85026534809 scopus 로고    scopus 로고
    • Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study
    • 7139718
    • Haag GM, Stocker G, Quidde J, Jaeger D, Lordick F. Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study. BMC Cancer 2017;17(1):509. 7139718
    • (2017) BMC Cancer , vol.17 , Issue.1 , pp. 509
    • Haag, G.M.1    Stocker, G.2    Quidde, J.3    Jaeger, D.4    Lordick, F.5
  • 184
    • 85035138698 scopus 로고    scopus 로고
    • Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial
    • 2974557
    • Malka D, Gourgou-Bourgade S, Emile J, Laurent-Puig P, Taieb J. Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial. Journal of Clinical Oncology 2011;29(15 Suppl):TPS178. 2974557
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.15 , pp. 178
    • Malka, D.1    Gourgou-Bourgade, S.2    Emile, J.3    Laurent-Puig, P.4    Taieb, J.5
  • 185
    • 85035119674 scopus 로고    scopus 로고
    • phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
    • (first received 10 August 2007). 2974563
    • NCT00515411. Study of modified docetaxel, cisplatin, and fluorouracil (mDCF) in unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma [A phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma]. clinicaltrials.gov/ct2/show/NCT00515411 (first received 10 August 2007). 2974563
  • 186
    • 84872650265 scopus 로고    scopus 로고
    • A phase III study for ErbB2 positive advanced or metastatic gastric, esophageal, or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapatinib
    • (first received 15 May 2008). 2974565
    • NCT00680901. LOGiC - lapatinib optimization study in ErbB2 (HER2) positive gastric cancer: a phase III global, blinded study designed to evaluate clinical endpoints and safety of chemotherapy plus lapatinib [A phase III study for ErbB2 positive advanced or metastatic gastric, esophageal, or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapatinib]. clinicaltrials.gov/ct2/show/NCT00680901 (first received 15 May 2008). 2974565
  • 187
    • 85035149450 scopus 로고    scopus 로고
    • A randomized phase II trial of capecitabine plus cisplatin (XP) versus capecitabine plus paclitaxel (XT) as a first-line treatment for advanced or recurrent esophageal squamous cell carcinoma
    • (first received 30 December 2008). 2974567
    • NCT00816634. Efficacy comparison study of combination regimens to treat advanced esophageal squamous cell carcinoma (XP versus XT) [A randomized phase II trial of capecitabine plus cisplatin (XP) versus capecitabine plus paclitaxel (XT) as a first-line treatment for advanced or recurrent esophageal squamous cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00816634 (first received 30 December 2008). 2974567
  • 188
    • 85035141152 scopus 로고    scopus 로고
    • REAL 3: a randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer
    • (first received 16 January 2009). 2974569
    • NCT00824785. REAL3 trial of efficacy of EOX with/without panitumumab in previously untreated adv OG cancer (REAL3) [REAL 3: a randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer]. clinicaltrials.gov/ct2/show/NCT00824785 (first received 16 January 2009). 2974569
  • 189
    • 85035111107 scopus 로고    scopus 로고
    • A randomized, double blind placebo controlled phase 2 study of FOLFOX plus or minus GDC-0449 in patients with advanced gastric and gastroesophageal junction (GEJ) carcinoma
    • (first received 22 September 2009). 2974571
    • NCT00982592. Combination chemotherapy with or without vismodegib in treating patients with advanced stomach cancer or gastroesophageal junction cancer [A randomized, double blind placebo controlled phase 2 study of FOLFOX plus or minus GDC-0449 in patients with advanced gastric and gastroesophageal junction (GEJ) carcinoma]. clinicaltrials.gov/ct2/show/NCT00982592 (first received 22 September 2009). 2974571
  • 190
    • 84940371678 scopus 로고    scopus 로고
    • A multicenter random assignment phase II study of irinotecan and alvocidib (flavopiridol) versus irinotecan alone for patients with p53 wild type gastric adenocarcinoma
    • (first received 7 October 2009). 2974573
    • NCT00991952. Irinotecan hydrochloride with or without alvocidib in treating patients with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery [A multicenter random assignment phase II study of irinotecan and alvocidib (flavopiridol) versus irinotecan alone for patients with p53 wild type gastric adenocarcinoma]. clinicaltrials.gov/ct2/show/NCT00991952 (first received 7 October 2009). 2974573
  • 191
    • 85035105200 scopus 로고    scopus 로고
    • A randomized, placebo-controlled phase II trial investigating SUNITINIB versus placebo in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus treated with chemotherapy FOLFIRI
    • (first received 23 November 2009). 2974575
    • NCT01020630. Sunitinib in patients with advanced gastric cancer and treated with FOLFIRI (SUN-CASE) [A randomized, placebo-controlled phase II trial investigating SUNITINIB versus placebo in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus treated with chemotherapy FOLFIRI]. clinicaltrials.gov/ct2/show/NCT01020630 (first received 23 November 2009). 2974575
  • 192
    • 84906571684 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, double-blind phase 2 study of mFOLFOX6 chemotherapy plus ramucirumab drug product(IMC-1121B) versus mFOLFOX6 plus placebo for advanced adenocarcinoma of the esophagus, gastroesophageal junction or stomach
    • (first received 8 November 2010). 2974577
    • NCT01246960. A study of ramucirumab in participants with gastric, esophageal, and gastroesophageal cancer [Randomized, placebo-controlled, double-blind phase 2 study of mFOLFOX6 chemotherapy plus ramucirumab drug product(IMC-1121B) versus mFOLFOX6 plus placebo for advanced adenocarcinoma of the esophagus, gastroesophageal junction or stomach]. clinicaltrials.gov/ct2/show/NCT01246960 (first received 8 November 2010). 2974577
  • 193
    • 85035098672 scopus 로고    scopus 로고
    • A randomized phase II trial of capecitabine plus cisplatin (XP) versus capecitabine plus genexol (XG) as a first-line treatment for advanced or recurrent esophageal squamous cell carcinoma
    • (first received 18 November 2011). 2974579
    • NCT01474642. Phase II trial of XP versus XG in advanced esophageal squamous cell carcinoma [A randomized phase II trial of capecitabine plus cisplatin (XP) versus capecitabine plus genexol (XG) as a first-line treatment for advanced or recurrent esophageal squamous cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01474642 (first received 18 November 2011). 2974579
  • 194
    • 84937894336 scopus 로고    scopus 로고
    • A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1(excision repair cross-complementing 1) for advanced/metastatic esophageal, gastric or gastroesophageal junction (GEJ) cancer
    • (first received 22 December 2011). 2974581
    • NCT01498289. S1201: combination chemo for patients w/advanced or metastatic esophageal, gastric, or gastroesophageal junction cancer [A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1(excision repair cross-complementing 1) for advanced/metastatic esophageal, gastric or gastroesophageal junction (GEJ) cancer]. clinicaltrials.gov/ct2/show/NCT01498289 (first received 22 December 2011). 2974581
  • 195
    • 84940402595 scopus 로고    scopus 로고
    • Pazopanib with 5-fluorouracil, leucovorin and oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized phase-ii-study of the arbeitsgemeinschaft internistische onkologie
    • (first received 22 December 2011). 2974583
    • NCT01503372. FLO +/- pazopanib as first-line treatment in advanced gastric cancer (PaFLO) [Pazopanib with 5-fluorouracil, leucovorin and oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized phase-ii-study of the arbeitsgemeinschaft internistische onkologie]. clinicaltrials.gov/ct2/show/NCT01503372 (first received 22 December 2011). 2974583
  • 196
    • 85035081250 scopus 로고    scopus 로고
    • An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer
    • (first received 13 June 2012). 2974587
    • NCT01627379. Cisplatin and 5-FU +/- panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer (POWER) [An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer]. clinicaltrials.gov/ct2/show/NCT01627379 (first received 13 June 2012). 2974587
  • 197
    • 85035150737 scopus 로고    scopus 로고
    • Combination treatment of S-1 with paclitaxel versus paclitaxel+cisplatin and 5-Fu+cisplatin as first-line treatment in advanced esophageal cancer
    • (first received 4 October 2012). 2974591
    • NCT01704690. Combination treatment of S-1 with paclitaxel in advanced esophageal cancer [Combination treatment of S-1 with paclitaxel versus paclitaxel+cisplatin and 5-Fu+cisplatin as first-line treatment in advanced esophageal cancer]. clinicaltrials.gov/ct2/show/NCT01704690 (first received 4 October 2012). 2974591
  • 198
    • 85035137221 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo controlled phase II study of FOLFOX +/- ziv-aflibercept in patients with advanced esophageal and gastric cancer
    • (first received 5 December 2012). 2974593
    • NCT01747551. FOLFOX +/- ziv-aflibercept for esophageal and gastric cancer [Randomized, double-blind, placebo controlled phase II study of FOLFOX +/- ziv-aflibercept in patients with advanced esophageal and gastric cancer]. clinicaltrials.gov/ct2/show/NCT01747551 (first received 5 December 2012). 2974593
  • 199
    • 85035119129 scopus 로고    scopus 로고
    • A randomized, phase II, placebo controlled study of GDC-0068, an inhibitor to Akt, in combination with fluoropyrimidine plus oxaliplatin in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
    • (first received 8 July 2013). 2974595
    • NCT01896531. A study of GDC-0068 in combination with fluoropyrimidine plus oxaliplatin in participants with advanced or metastatic gastric or gastroesophageal junction cancer [A randomized, phase II, placebo controlled study of GDC-0068, an inhibitor to Akt, in combination with fluoropyrimidine plus oxaliplatin in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma]. clinicaltrials.gov/ct2/show/NCT01896531 (first received 8 July 2013). 2974595
  • 200
    • 84930821023 scopus 로고    scopus 로고
    • A phase 3, multicenter, randomized, double-blind, placebo controlled study of rilotumumab (AMG 102) with cisplatin and capecitabine (CX) as first-line therapy in advanced MET-positive gastric or gastroesophageal junction adenocarcinoma
    • (first received 28 April 2014). 2974597
    • NCT02137343. A phase 3 study of rilotumumab (AMG 102) with cisplatin and capecitabine (CX) as first-line therapy in gastric cancer (RILOMET-2) [A phase 3, multicenter, randomized, double-blind, placebo controlled study of rilotumumab (AMG 102) with cisplatin and capecitabine (CX) as first-line therapy in advanced MET-positive gastric or gastroesophageal junction adenocarcinoma]. Clinicaltrials.gov/ct2/show/NCT02137343 (first received 28 April 2014). 2974597
  • 201
    • 85035136267 scopus 로고    scopus 로고
    • Study assessing the effects of chemotherapy in advanced esophagogastric adenocarcinoma - carboplatin, docetaxel and capecitabine (CTX) or epirubicin, oxaliplatin and capecitabine: a randomised phase 2 trial
    • (first received 18 June 2014). 2974599
    • NCT02177552. Study assessing the effects of chemotherapy in advanced esophagogastric adenocarcinoma (SEED) [Study assessing the effects of chemotherapy in advanced esophagogastric adenocarcinoma - carboplatin, docetaxel and capecitabine (CTX) or epirubicin, oxaliplatin and capecitabine: a randomised phase 2 trial]. clinicaltrials.gov/ct2/show/NCT02177552 (first received 18 June 2014). 2974599
  • 202
    • 85035129054 scopus 로고    scopus 로고
    • A phase III clinical trial of BBI608 plus weekly paclitaxel vs. placebo plus weekly paclitaxel in adult patients with advanced, previously treated gastric and gastro-esophageal junction adenocarcinoma
    • (first received 27 June 2014). 2974601
    • NCT02178956. A study of BBI608 plus weekly paclitaxel to treat gastric and gastro-esophageal junction cancer (BRIGHTER) [A phase III clinical trial of BBI608 plus weekly paclitaxel vs. placebo plus weekly paclitaxel in adult patients with advanced, previously treated gastric and gastro-esophageal junction adenocarcinoma]. clincaltrials.gov/ct2/show/NCT02178956 (first received 27 June 2014). 2974601
  • 203
    • 84930819317 scopus 로고    scopus 로고
    • A phase I and randomized phase II double blinded placebo controlled study of mFOLFOX6 +/- AMG 337 in the first line treatment of patients with Her2/Neu negative and high MET expressing advanced gastric and esophageal adenocarcinoma
    • (first received 16 January 2015). 2974603
    • NCT02344810. C-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium, and fluorouracil in treating patients with advanced stomach or esophageal cancer [A phase I and randomized phase II double blinded placebo controlled study of mFOLFOX6 +/- AMG 337 in the first line treatment of patients with Her2/Neu negative and high MET expressing advanced gastric and esophageal adenocarcinoma]. clinicaltrials.gov/ct2/show/NCT02344810 (first received 16 January 2015). 2974603
  • 204
    • 85035085213 scopus 로고    scopus 로고
    • Randomized phase II study of octreotide LAR as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas
    • (first received 1 April 2015). 2974605
    • NCT02409849. Octreotide LAR as maintenance treatment for patients with NEC [Randomized phase II study of octreotide LAR as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas]. clinicaltrials.gov/ct2/show/NCT02409849 (first received 1 April 2015). 2974605
  • 205
    • 85035135411 scopus 로고    scopus 로고
    • ONO-4538 phase III study a multicenter, randomized, open-label study in patients with unresectable advanced or recurrent esophageal cancer
    • (first received 6 October 2015). 7139720
    • NCT02569242. Study of nivolumab in unresectable advanced or recurrent esophageal cancer [ONO-4538 phase III study a multicenter, randomized, open-label study in patients with unresectable advanced or recurrent esophageal cancer]. clinicaltrials.gov/show/NCT02569242 (first received 6 October 2015). 7139720
  • 207
    • 85035143615 scopus 로고    scopus 로고
    • A phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction
    • (first received 9 December 2015). 7139723
    • NCT02625610. Avelumab in first-line maintenance gastric cancer (JAVELIN Gastric 100) [A phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction]. clinicaltrials.gov/show/NCT02625610 (first received 9 December 2015). 7139723
  • 208
    • 85035146991 scopus 로고    scopus 로고
    • JAVELIN gastric 300: phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer
    • 7139725
    • Eric VC, Lucjan W, Keun-Wook L, Fortunato C, Rosine G, Julien T, et al. JAVELIN gastric 300: phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer. Annals of Oncology 2015;27:ii82. 7139725
    • (2015) Annals of Oncology , vol.27 , pp. 82
    • Eric, V.C.1    Lucjan, W.2    Keun-Wook, L.3    Fortunato, C.4    Rosine, G.5    Julien, T.6
  • 209
    • 85035104759 scopus 로고    scopus 로고
    • A randomized, multicenter, double blind, phase iii study of adjuvant nivolumab or placebo in subjects with resected esophageal, or gastroesophageal junction cancer
    • (first received 19 April 2016). 7139727
    • NCT02743494. An investigational immuno-therapy study of nivolumab or placebo in patients with resected esophageal or gastroesophageal junction cancer (CheckMate 577) [A randomized, multicenter, double blind, phase iii study of adjuvant nivolumab or placebo in subjects with resected esophageal, or gastroesophageal junction cancer]. clinicaltrials.gov/show/NCT02743494 (first received 19 April 2016). 7139727
  • 210
    • 85036497908 scopus 로고    scopus 로고
    • Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) An international study organized by the Australasian Gastrointestinal Trials Group (AGITG)
    • 7139729
    • Sjoquist KM, Pavlakis N, Martin AJ, Tsobanis E, Yip S, Bang YJ, et al. Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) An international study organized by the Australasian Gastrointestinal Trials Group (AGITG). Journal of Clinical Oncology 2016 [Epub ahead of print]; Vol. 35, issue 15. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS4136]7139729
    • (2016) Journal of Clinical Oncology , vol.35 , Issue.15
    • Sjoquist, K.M.1    Pavlakis, N.2    Martin, A.J.3    Tsobanis, E.4    Yip, S.5    Bang, Y.J.6
  • 211
    • 85021165156 scopus 로고    scopus 로고
    • CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer
    • 19 Aug 2016 [Epub ahead of print], 7139731
    • Moehler MH, Janjigian YY, Adenis A, Aucoin JS, Boku N, Chau I, et al. CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer. Journal of Clinical Oncology 19 Aug 2016 [Epub ahead of print]; Vol. 35, issue 15. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS213]7139731
    • Journal of Clinical Oncology , vol.35 , Issue.15
    • Moehler, M.H.1    Janjigian, Y.Y.2    Adenis, A.3    Aucoin, J.S.4    Boku, N.5    Chau, I.6
  • 212
    • 85035080285 scopus 로고    scopus 로고
    • Docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin as first-line treatment for metastatic esophageal squamous patients: a prospective multicenter, randomized controlled clinical study
    • (first received 23 December 2016). 7139733
    • NCT03002064. Docetaxol plus cisplatin versus 5-Fu plus cisplatin as 1st-line chemotherapy in advanced ESCC patients [Docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin as first-line treatment for metastatic esophageal squamous patients: a prospective multicenter, randomized controlled clinical study]. clinicaltrials.gov/show/NCT03002064 (first received 23 December 2016). 7139733
  • 213
    • 85028530303 scopus 로고    scopus 로고
    • Essai de phase iii randomise evaluant le folfox avec ou sans docetaxel (tfox) en 1ère ligne de chimiotherapie des adenocarcinomes oeso-gastriques localement avances ou metastatiques
    • (first received 30 December 2016). 7139735
    • NCT03006432. Phase III randomised trial to evaluate folfox with or without docetaxel (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric carcinoma (GASTFOX) [Essai de phase iii randomise evaluant le folfox avec ou sans docetaxel (tfox) en 1ère ligne de chimiotherapie des adenocarcinomes oeso-gastriques localement avances ou metastatiques]. clinicaltrials.gov/show/NCT03006432 (first received 30 December 2016). 7139735
  • 214
    • 85035141453 scopus 로고    scopus 로고
    • A phase III, randomized, open-label clinical trial of pembrolizumab (MK-3475) versus paclitaxel in Asian subjects with advanced gastric or gastroesophageal junction adenocarcinoma who progressed after first-line therapy with platinum and fluoropyrimidine
    • (first received 12 January 2017). 7139737
    • NCT03019588. Efficacy and safety study of pembrolizumab (MK-3475) versus paclitaxel in Asian participants with advanced gastric or gastroesophageal junction adenocarcinoma who progressed after first-line therapy with platinum and fluoropyrimidine (MK-3475-063/KEYNOTE-063) [A phase III, randomized, open-label clinical trial of pembrolizumab (MK-3475) versus paclitaxel in Asian subjects with advanced gastric or gastroesophageal junction adenocarcinoma who progressed after first-line therapy with platinum and fluoropyrimidine]. clinicaltrials.gov/show/NCT03019588 (first received 12 January 2017). 7139737
  • 215
    • 85036497908 scopus 로고    scopus 로고
    • A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study
    • 3 Feb 2017 [Epub ahead of print], 7139739
    • Kang YK, Boku N, Kang WK, Yoon HH, Cascinu S, Al-Batran SE, et al. A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study. Journal of Clinical Oncology 3 Feb 2017 [Epub ahead of print]; Vol. 35, issue 15. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS4138]7139739
    • Journal of Clinical Oncology , vol.35 , Issue.15
    • Kang, Y.K.1    Boku, N.2    Kang, W.K.3    Yoon, H.H.4    Cascinu, S.5    Al-Batran, S.E.6
  • 216
    • 85035083156 scopus 로고    scopus 로고
    • A randomized, controlled phase II study to compare irinotecan combined with cisplatin (IP) versus etoposide combined with cisplatin (EP) in advanced and metastatic gastrointestinal pancreatic and esophageal neuroendocrine carcinoma
    • (first received 30 May 2017). 7139741
    • NCT03168594. Study to compare irinotecan combined with cisplatin (IP) versus etoposide combined with cisplatin (EP) in advanced and metastatic gastrointestinal pancreatic and esophageal neuroendocrine carcinoma [A randomized, controlled phase II study to compare irinotecan combined with cisplatin (IP) versus etoposide combined with cisplatin (EP) in advanced and metastatic gastrointestinal pancreatic and esophageal neuroendocrine carcinoma]. clinicaltrials.gov/show/NCT03168594 (first received 30 May 2017). 7139741
  • 217
    • 85035086126 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination with cisplatin and 5-fluorouracil versus placebo in combination with cisplatin and 5-fluorouracil as first-line treatment in subjects with advanced/metastatic esophageal carcinoma (KEYNOTE-590)
    • (first received 16 June 2017). 7139743
    • NCT03189719. First-line esophageal carcinoma study with chemo vs. chemo plus pembrolizumab (MK-3475-590/KEYNOTE-590) [A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination with cisplatin and 5-fluorouracil versus placebo in combination with cisplatin and 5-fluorouracil as first-line treatment in subjects with advanced/metastatic esophageal carcinoma (KEYNOTE-590)]. clinicaltrials.gov/show/NCT03189719 (first received 16 June 2017). 7139743
  • 218
    • 85035090059 scopus 로고    scopus 로고
    • A randomized, controlled phase II study to compare capecitabine combined with dacarbazine (CAPDTIC) versus capecitabine combined temozolomide (CAPTEM) in advanced and metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor
    • (first received 12 September 2017). 7139745
    • NCT03279601. Study to compare capecitabine combined with dacarbazine (CAPDTIC) versus capecitabine combined temozolomide (CAPTEM) in advanced and metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor [A randomized, controlled phase II study to compare capecitabine combined with dacarbazine (CAPDTIC) versus capecitabine combined temozolomide (CAPTEM) in advanced and metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor]. clinicaltrials.gov/show/NCT03279601 (first received 12 September 2017). 7139745
  • 219
    • 85035151630 scopus 로고    scopus 로고
    • A phase Ib/II, open-label, multicenter, randomized, umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (morpheus-gastric cancer)
    • (first received 13 September 2017). 7139747
    • NCT03281369. A study of multiple immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (G/GEJ) (UMBRELLA) [A phase Ib/II, open-label, multicenter, randomized, umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (morpheus-gastric cancer)]. clinicaltrials.gov/show/NCT03281369 (first received 13 September 2017). 7139747
  • 220
    • 85035106193 scopus 로고    scopus 로고
    • KEYNOTE-061: pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
    • 7139749
    • Ohtsu A, Tabernero J, Bang YJ, Fuchs CS, Sun L, Wang Z, et al. KEYNOTE-061: pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology 2015;26(9 Suppl):ix69. 7139749
    • (2015) Annals of Oncology , vol.26 , Issue.9 , pp. 69
    • Ohtsu, A.1    Tabernero, J.2    Bang, Y.J.3    Fuchs, C.S.4    Sun, L.5    Wang, Z.6
  • 221
    • 85035118925 scopus 로고    scopus 로고
    • A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma
    • 7139751
    • Shah MA, Metges JP, Chun PY, Smith V, Maltzman JD, Wainberg ZA. A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology 2017;35(15 Suppl):TPS4141. 7139751
    • (2017) Journal of Clinical Oncology , vol.35 , Issue.15 , pp. 4141
    • Shah, M.A.1    Metges, J.P.2    Chun, P.Y.3    Smith, V.4    Maltzman, J.D.5    Wainberg, Z.A.6
  • 222
    • 84890279606 scopus 로고    scopus 로고
    • Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: an international phase III study (JACOB)
    • 2974607
    • Tabernero J, Hoff PM, Shen L, Ohtsu A, Yu R, Eng-Wong J, Kang YK. Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: an international phase III study (JACOB). Journal of Clinical Oncology 2013;31(15 Suppl):TPS4150. 2974607
    • (2013) Journal of Clinical Oncology , vol.31 , Issue.15 , pp. 4150
    • Tabernero, J.1    Hoff, P.M.2    Shen, L.3    Ohtsu, A.4    Yu, R.5    Eng-Wong, J.6    Kang, Y.K.7
  • 223
    • 85015645736 scopus 로고    scopus 로고
    • KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
    • 7139753
    • Tabernero J, Bang YJ, Fuchs CS, Ohtsu A, Kher U, Lam B, et al. KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology 2016;34(4):TPS185. 7139753
    • (2016) Journal of Clinical Oncology , vol.34 , Issue.4 , pp. 185
    • Tabernero, J.1    Bang, Y.J.2    Fuchs, C.S.3    Ohtsu, A.4    Kher, U.5    Lam, B.6
  • 224
    • 85035131611 scopus 로고    scopus 로고
    • Pembrolizumab versus physician-choice chemotherapy for previously treated patients with advanced/metastatic squamous or adenocarcinoma of the esophagus or Siewert I adenocarcinoma of the esophagogastric junction (EGJ): randomized, phase 3 KEYNOTE-18
    • 7139755
    • Toshihiko D, Jaafar B, Lin S, Peter E, Ruixue W, Ildiko C, et al. Pembrolizumab versus physician-choice chemotherapy for previously treated patients with advanced/metastatic squamous or adenocarcinoma of the esophagus or Siewert I adenocarcinoma of the esophagogastric junction (EGJ): randomized, phase 3 KEYNOTE-18. Annals of Oncology 2016;27(2 Suppl):i81. 7139755
    • (2016) Annals of Oncology , vol.27 , Issue.2 , pp. 81
    • Toshihiko, D.1    Jaafar, B.2    Lin, S.3    Peter, E.4    Ruixue, W.5    Ildiko, C.6
  • 225
    • 0027417437 scopus 로고
    • The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
    • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993;85(5):365-76.
    • (1993) Journal of the National Cancer Institute , vol.85 , Issue.5 , pp. 365-376
    • Aaronson, N.K.1    Ahmedzai, S.2    Bergman, B.3    Bullinger, M.4    Cull, A.5    Duez, N.J.6
  • 226
    • 0035963980 scopus 로고    scopus 로고
    • Systematic reviews of evaluations of prognostic variables
    • Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323(7306):224-8.
    • (2001) BMJ , vol.323 , Issue.7306 , pp. 224-228
    • Altman, D.G.1
  • 227
    • 84875914987 scopus 로고    scopus 로고
    • Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review
    • Amdal CD, Jacobsen A, Guren MGN, Bjordal K. Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. Acta Oncologica 2013;52(4):679-90.
    • (2013) Acta Oncologica , vol.52 , Issue.4 , pp. 679-690
    • Amdal, C.D.1    Jacobsen, A.2    Guren, M.G.N.3    Bjordal, K.4
  • 228
    • 84922383906 scopus 로고    scopus 로고
    • Global incidence of oesophageal cancer by histological subtype in 2012
    • Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2015;64(3):381-7.
    • (2015) Gut , vol.64 , Issue.3 , pp. 381-387
    • Arnold, M.1    Soerjomataram, I.2    Ferlay, J.3    Forman, D.4
  • 230
    • 0035673978 scopus 로고    scopus 로고
    • Measurement of outcome
    • Blazeby JM. Measurement of outcome. Surgical Oncology 2001;10(3):127-33.
    • (2001) Surgical Oncology , vol.10 , Issue.3 , pp. 127-133
    • Blazeby, J.M.1
  • 231
    • 0038798871 scopus 로고    scopus 로고
    • Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer
    • Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. European Journal of Cancer 2003;39(10):1384-94.
    • (2003) European Journal of Cancer , vol.39 , Issue.10 , pp. 1384-1394
    • Blazeby, J.M.1    Conroy, T.2    Hammerlid, E.3    Fayers, P.4    Sezer, O.5    Koller, M.6
  • 232
    • 5344256928 scopus 로고    scopus 로고
    • Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer
    • Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. European Journal of Cancer 2004;40(15):2260-8.
    • (2004) European Journal of Cancer , vol.40 , Issue.15 , pp. 2260-2268
    • Blazeby, J.M.1    Conroy, T.2    Bottomley, A.3    Vickery, C.4    Arraras, J.5    Sezer, O.6
  • 233
    • 65549103309 scopus 로고    scopus 로고
    • The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma - 025EF individual patient data from 1775 patients in four randomised controlled trials
    • Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma - 025EF individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology 2009;20(5):885-91.
    • (2009) Annals of Oncology , vol.20 , Issue.5 , pp. 885-891
    • Chau, I.1    Norman, A.R.2    Cunningham, D.3    Oates, J.4    Hawkins, R.5    Iveson, T.6
  • 234
    • 70350238222 scopus 로고    scopus 로고
    • Common Terminology Criteria for Adverse Events v 4.0
    • Bethesda, MD: National Institutes of Health, National Cancer Institute; May. NIH publication #09-7473
    • National Cancer Institute. Common Terminology Criteria for Adverse Events v 4.0. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2009 May. NIH publication #09-7473.
    • (2009)
  • 235
    • 70249118103 scopus 로고    scopus 로고
    • Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005
    • Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. British Journal of Cancer 2009;101(5):855-9.
    • (2009) British Journal of Cancer , vol.101 , Issue.5 , pp. 855-859
    • Cook, M.B.1    Chow, W.H.2    Devesa, S.S.3
  • 236
    • 84877689938 scopus 로고    scopus 로고
    • A global assessment of the oesophageal adenocarcinoma epidemic
    • Edgren G, Adami HO, Vainio EW, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013;62(10):1406-14.
    • (2013) Gut , vol.62 , Issue.10 , pp. 1406-1414
    • Edgren, G.1    Adami, H.O.2    Vainio, E.W.3    Nyren, O.4
  • 238
    • 0025688231 scopus 로고
    • EuroQol--a new facility for the measurement of health-related quality of life
    • EuroQol group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-208.
    • (1990) Health Policy , vol.16 , Issue.3 , pp. 199-208
  • 240
    • 63849105841 scopus 로고    scopus 로고
    • Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)
    • editors. Chichester, UK: John Wiley & Sons, Ltd
    • Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester, UK: John Wiley & Sons, Ltd.
    • (2011) The Cochrane Collaboration
    • Higgins, J.P.1    Green, S.2
  • 241
    • 79958043675 scopus 로고    scopus 로고
    • SEER Cancer Statistics Review 1975-2011
    • Bethesda, MD: National Institutes of Health, National Cancer Institute; April, editors
    • Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. editors. SEER Cancer Statistics Review 1975-2011. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2014 April. [http://seer.cancer.gov/csr/1975_2011/]
    • (2014)
    • Howlader, N.1    Noone, A.M.2    Krapcho, M.3    Garshell, J.4    Miller, D.5    Altekruse, S.F.6
  • 242
    • 84874739298 scopus 로고    scopus 로고
    • Trends in esophageal adenocarcinoma incidence and mortality
    • Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119(6):1149-58.
    • (2013) Cancer , vol.119 , Issue.6 , pp. 1149-1158
    • Hur, C.1    Miller, M.2    Kong, C.Y.3    Dowling, E.C.4    Nattinger, K.J.5    Dunn, M.6
  • 245
    • 0031004542 scopus 로고    scopus 로고
    • Thirty years of Medical Research Council randomised trials in solid tumors
    • Machin D, Stenning SP, Parmar MKP. Thirty years of Medical Research Council randomised trials in solid tumors. Journal of Clinical Oncology 1997;9(2):100-14.
    • (1997) Journal of Clinical Oncology , vol.9 , Issue.2 , pp. 100-114
    • Machin, D.1    Stenning, S.P.2    Parmar, M.K.P.3
  • 247
    • 84942195697 scopus 로고    scopus 로고
    • Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
    • Mohammad NH, ter Veer E, Ngai L, Mali R, van Oijen MG, van Laarhoven HW. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. Cancer Metastasis Reviews 2015;34(3):429-41.
    • (2015) Cancer Metastasis Reviews , vol.34 , Issue.3 , pp. 429-441
    • Mohammad, N.H.1    ter Veer, E.2    Ngai, L.3    Mali, R.4    van Oijen, M.G.5    van Laarhoven, H.W.6
  • 248
    • 68049122102 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    • Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 2009;6(7):1-7. [DOI: 10.1371/journal.pmed.1000097]
    • (2009) PLOS Medicine , vol.6 , Issue.7 , pp. 1-7
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 250
    • 0032583387 scopus 로고    scopus 로고
    • Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints
    • Parmar MKB, Torri V, Steward L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17(28):15-34.
    • (1998) Statistics in Medicine , vol.17 , Issue.28 , pp. 15-34
    • Parmar, M.K.B.1    Torri, V.2    Steward, L.3
  • 251
    • 84914179053 scopus 로고    scopus 로고
    • R: A Language and Environment for Statistical Computing
    • Version 3.1.2. Vienna, Austria: R Foundation for Statistical Computing
    • R Core Team. R: A Language and Environment for Statistical Computing. Version 3.1.2. Vienna, Austria: R Foundation for Statistical Computing, 2014.
    • (2014)
  • 252
    • 84964921069 scopus 로고    scopus 로고
    • Review Manager (RevMan)
    • Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration
    • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
    • (2014)
  • 256
    • 62849113100 scopus 로고    scopus 로고
    • Stents as sole therapy for oesophageal cancer: a prospective analysis of outcomes after placement
    • White RE, Parker RK, Fitzwater JW, Kasepoi Z, Topazian M. Stents as sole therapy for oesophageal cancer: a prospective analysis of outcomes after placement. Lancet Oncology 2009;10(3):240-6.
    • (2009) Lancet Oncology , vol.10 , Issue.3 , pp. 240-246
    • White, R.E.1    Parker, R.K.2    Fitzwater, J.W.3    Kasepoi, Z.4    Topazian, M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.